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Summary 
Elimination of unwanted or damaged cells through apoptosis is critical during the embryonic 
development, in the immune system and to maintain tissue homeostasis in multicellular 
organisms. Apoptosis is strictly regulated by pro- and anti-apoptotic proteins. c-FLIP proteins 
inhibit death receptor-mediated apoptosis at the death-inducing signalling complex (DISC) by 
preventing caspase-8-processing. The aim of this thesis is to gain a better understanding of 
c-FLIP proteins’ role in disease and to examine if there are unknown DISC-interacting 
proteins which could give a better insight into the complex signalling of the CD95 receptor. 
Deregulation of apoptosis is common in cancer and is often caused by overexpression of anti-
apoptotic proteins in tumour cells. The role of c-FLIP splice variants c-FLIPL and c-FLIPS in 
urothelial carcinoma was examined in this thesis. Unexpectedly, the c-FLIPL isoform was 
down-regulated in urothelial carcinoma tissues as well as in established carcinoma cell lines 
compared with normal urothelial tissues and cells, whereas c-FLIPS was unchanged. 
Nevertheless, both overexpression and knock-down through RNA interference of c-FLIP 
isoforms demonstrated that c-FLIP proteins, particularly c-FLIPL, are central resistance 
factors against CD95- and TRAIL-mediated apoptosis in urothelial tumours. 
Non-apoptotic functions of CD95 DISC-interacting proteins have been described, including 
NF-κB activation, proliferation and T cell activation. However, the signalling mechanisms 
and how these proteins switch between apoptotic and survival signalling are not clear. The 
CD95 DISC was analysed by mass spectrometry to gain further insights into the DISC 
composition and the influence of c-FLIPL. Interestingly, TRAF2 and RIP1 were recruited to 
the DISC in a c-FLIPL-dependent manner. Moreover, the novel CD95 DISC-binding protein 
A20 was identified and its DISC interaction was verified by Western blotting. 
c-FLIPR is the solely short c-FLIP isoform expressed in mice. Endogenous c-FLIPR was 
induced upon T cell stimulation with kinetics similar to c-FLIPS in humans. The mouse model 
vavFLIPR with constitutive expression of murine c-FLIPR was used to examine the functional 
role of c-FLIPR in the immune system. Lymphocytes from vavFLIPR mice were protected 
against CD95-mediated apoptosis, thus confirming functional c-FLIPR expression. Increased 
antigen-experienced and diminished naïve T cell populations were identified in one-year-old 
vavFLIPR mice in comparison to wild-type mice. Moreover, higher levels of kidney damage 
and elevated autoantibody titers were observed in vavFLIPR animals compared with wild-type 
littermates, suggesting a mild lupus-like phenotype of vavFLIPR mice. 
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1.  Introduction 
1.1. Cell death mechanisms 
Cell death plays a crucial role in the embryonic development and for regulation of tissue 
homeostasis in multicellular organisms by removal of unwanted or damaged cells. There are 
different modes of cell death depending on the stimulation and environment of the cell 1. Cell 
death has long been postulated to either be regulated (apoptosis) or unregulated (necrosis). 
However, other non-apoptotic regulated cell death pathways such as necroptosis and 
autophagic cell death have also been described 2.  
Apoptosis and necrosis can be discriminated through distinct morphological and biochemical 
characteristics 3. Before Kerr, Wyllie and Currie described apoptosis in 1972 4, all kinds of 
cell death was termed necrosis and apoptosis was first called ‘shrinkage necrosis’ due to the 
morphological features of dying cells 3. Cells undergoing apoptosis are characterised by cell 
size reduction, chromatin condensation, nuclear fragmentation, membrane blebbing and 
formation of apoptotic bodies, which can be efficiently phagocytosed 3, 5 (Figure 1). In 
contrast, necrotic cell death is characterised by swelling of the cytoplasm and organelles, 
massive oxidative stress and rupture of the plasma membrane 3. The lost cell integrity allows 
intracellular contents to leak to the extracellular space and attract immune cells 3, 6 (Figure 1). 
Apoptosis is an evolutionarily conserved process driven by numerous apoptosis-regulating 
genes 7. External stress such as withdrawal of growth factors, irradiation or cytotoxic drugs 
can induce apoptosis 8. Further, death ligands of immune cells can trigger apoptosis 
signalling 8. Apoptotic cells release ‘find me’ signals such as the chemoattractant lipid 
lysophosphatidylcholine to recruit phagocytic cells i.e. dendritic cells and macrophages 9. As 
cells undergo apoptosis, the strict organisation of the phospholipids in the plasma membrane 
is disrupted. The phospholipid phosphatidylserine (PS) is located on the inside of the plasma 
membrane in healthy cells, but becomes exposed to the outside of the cell during apoptosis 
and is detected by phagocytes as an ‘eat me’ signal 10, 11. Changes in carbohydrate 
composition of the plasma membrane and oxidised lipids are other engulfment signals. 
Phagocytic cells indirectly bind to the apoptotic cell through bridging molecules such as milk 
fat globule–EGF factor-8 protein (MFG-E8) and T cell immunoglobin domain and mucin 
domain protein 4 (TIM4) 12, 13. Phagocytes can also directly bind apoptotic cells by receptors 
recognising ‘eat me’ signals, for instance thrombospondin (TSP) and the scavenger receptors 
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CD36, SR-A and LOX1 14-18. Macrophage lectins and integrins presumably also recognise 
apoptotic cells 19-21. Other possible molecules/ligands acting as engulfment signals on dying 
cells are AnnexinI and the adhesion molecule intercellular adhesion molecule-3 (ICAM3) 22, 
23
. 
The absence of an inflammatory response is a further characteristic of apoptosis. The 
apoptotic cells are able to provide an anti-inflammatory environment by inducing 
macrophages to produce the anti-inflammatory cytokines transforming growth factor β 
(TGF-β) and interleukin 10 (IL-10), which ensures a ‘silent’ death without inflammation 24.  
 
 
Figure 1. Cell death mechanisms. Necrosis is characterised by swelling of the cytoplasm and organelles. 
The membrane integrity is lost and intracellular contents leak to the extracellular space. In contrast, the 
apoptotic cell shrinks, DNA is fragmented and the membrane blebs. Further, apoptotic bodies are formed to 
facilitate phagocytosis. In autophagy, cellular contents are enclosed by a double-layer membrane forming 
the autophagosome. The autophagosome subsequently fuses with the lysosome and thereby degrades its 
contents. 
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Turning to necrosis, this cell death mode can be induced by direct cell trauma or harmful 
conditions such as hyperthermia, hypoxia, ischemia or toxic substances 25. Moreover, stress 
can be sensed by the level of reactive oxygen species (ROS) production, increase in 
intracellular Ca2+ levels and depletion of intracellular ATP 26. Several of these factors can also 
induce apoptosis. It presumably depends on the intensity level of the stimuli if apoptosis or 
necrosis is induced with low doses triggering apoptosis, whereas higher doses results in 
necrosis 26. Necrosis is an immunogenic type of cell death. Inflammation is promoted by the 
passive release of high mobility group protein B1 (HMGB1), uric acid, heat shock proteins, 
genomic DNA and other molecules which attract innate immune cells such as dendritic cells, 
macrophages, natural killer cells (NK cells) and neutrophils 5, 26, 27. Recently, a strictly 
regulated cell death mechanism with features of necrosis was identified and named 
necroptosis. If apoptosis is blocked, necroptosis can be induced by the same death ligands 
triggering apoptosis, which could be a back-up mechanism to ensure cell death 28.  
Autophagy is an intracellular process where parts of the cell can be digested to recycle 
nutrients or to remove damaged or unwanted organelles 29. Moreover, intracellular pathogens 
can be eliminated by this pathway 29. In autophagy, a double-layered membrane encloses the 
cytoplasmic contents to be removed 29. The vesicle formed is called the autophagosome, 
which subsequently fuses with the lysosome to degrade its contents 29 (Figure 1). Autophagy 
is a survival mechanism which is induced due to starvation of the cell. However, increased 
autophagic flux can also be observed in dying cells. Autophagic cell death is morphologically 
characterised by massive cytoplasmic vacuolisation indicating an elevated autophagic flux 30. 
Nevertheless, the existence of autophagic cell death has been lively debated. Presumably, in 
most cases autophagy is induced during cell death and is not actually executing the cell 31. 
1.2. Apoptosis 
Apoptosis is essential in embryonic development and for maintaining tissue homeostasis 32. 
Efficient elimination of cells by apoptosis is also crucial in the immune system, for instance in 
negative selection of T cells in the thymus and during the contraction phase of immune 
responses 33, 34. Moreover, apoptosis can act as a defence against viral and bacterial pathogens 
by eliminating infected cells before pathogens spread to other cells 5, 6, 33. There are two 
distinct pathways leading to apoptosis, the extrinsic and the intrinsic pathway 35, 36. These 
signalling pathways involve numerous proteins; especially the caspase and Bcl-2 family 
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members are important mediators of apoptosis 5, 32. The apoptosis pathways and involved 
proteins are described below. 
1.2.1. Caspases – mediators of apoptosis 
The cysteine proteases, called caspases, play a central role in the apoptotic machinery. Since 
the discovery of caspase-1 and its functional homologue CED-3 in Caenorhabditis elegans 
(C. elegans) in the early 1990’s, a whole field of caspase research has developed 37-39. So far 
12 functional human caspases (caspase-1-10, 14 and 16) and 11 murine caspases (caspase-1, 
2, 3, 6, 7, 8, 9, 11, 12, 14 and 16) have been identified 40, 41. There are some differences 
between the human and murine caspases; caspase-10 is absent in the mouse genome and 
murine caspase-11 and -12 are the functional homologues of human caspase-4 and -5, 
respectively 40, 41. Human caspase-8 has two functional splice variants; caspase-8/a and the 15 
amino acid smaller caspase-8/b 42. Moreover, most humans have a polymorphism in caspase-
12 which results in a truncated protein mainly consisting of the caspase recruitment domain 
(CARD)-domain (caspase-12S). However, there are individuals of African origin who express 
the enzymatically inactive full-length caspase-12L 43. Presumably, human caspase-12 function 
as a dominant-negative regulator of pro-inflammatory responses 44.  
Caspases consist of a prodomain followed by a large subunit (p20) and a small subunit (p10) 
with a cleavage site in-between the large and small subunits 45. All caspases contain the 
catalytic residues His-237 and Cys-285, with numbering originating from human caspase-1 46. 
The active site consists of a pentapeptide QACXG (where X denotes R, Q or G), including 
Cys-285 45, 47. The caspases are categorised into groups according to their function in 
apoptosis or inflammation (Figure 2). The apoptotic caspases are subdivided into the initiator 
caspases 2, 8, 9 and 10, and the effector caspases 3, 6 and 7. The inflammatory caspases are 
caspases 1, 4, 5, 11 and 12 45.  Although caspase-14 and -16 are genetically closely related 
and caspase-14 is involved in terminal keratinocyte differentiation 48, 49, caspase-16 was not 
expressed in epidermal keratinocytes 40. Thus, the function of caspase-16 remains to be 
investigated. The apical caspases are present as inactive monomeric zymogens in the cell and 
are activated by proteolytical cleavage or dimerisation. Recruitment to signalling platforms 
via their death effector domain (DED) and CARD recruitment domains facilitates 
dimerisation and thereby activation 50, 51. In contrast, the effector caspases exist as inactive 
dimers 41, 45. Proteolytical cleavage of the intersubunit linker by an initiator caspase or another 
protease activates the effector caspases 41, 45.  
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Figure 2. Structural overview of 
human (hu) and murine (ms) 
caspases. The caspases are divided 
into the apoptotic initiator and 
effector caspases as well as the 
inflammatory caspases. The initiator 
caspases 2, 8, 9 and 10 have a large 
C-terminal prodomain containing 
DED and CARD domains which are 
important for recruitment to signalling 
platforms. Caspases 3, 6 and 7 are 
effector caspases, whereas caspase-1, 
-4, -5, -11 and -12 are inflammatory 
caspases. Human caspase-12 contains 
a polymorphism, resulting in a 
truncated splice variant of caspase 12, 
which mainly consists of the CARD 
domain. Some individuals of African 
origin express catalytically inactive 
full-length caspase-12. Caspase-14 
plays an important role in terminal 
keratinocyte differentiation. Adapted 
from Fuentes- Prior and Salvesen, 
2004 45. 
 
Caspases cleave their substrates after a tetrapeptide sequence, P4-P3-P2-P1, with an aspartate 
in the P1 position 52. The caspases have different tetrapeptide sequence specificities: the 
inflammatory caspases 1, 4 and 5 have a preference for the (W/L)EXD motif (X denotes any 
amino acid residue), caspase-3, -7 and -2 favour the sequence DEXD and the preferential 
tetrapeptide sequence of caspases 6, 8, 9 and 10 is (L/I/V)EXD 41, 45, 52. The different cleavage 
preferences are also reflected in the substrate specificities of caspases. The pro-inflammatory 
caspases differ from the apoptotic caspases in that they regulate both cytokine processing and 
apoptosis. Recruitment of caspase-1 the inflammasome mediates activation of this caspase 
and active caspase-1 subsequently activates the cytokines IL-1β and IL-18 by processing of 
their proforms 44. The initiator and effector apoptotic caspases differ in their substrate 
specificities in that initiator caspases cleave few specific substrates, whereas effector caspases 
process numerous substrates during the demolition phase of apoptosis 41, 53. A substantial part 
of the morphological and biochemical changes of the cell during apoptosis are mediated by 
caspase cleavage 5, 53. The rounding up and contraction of the cell seen in early stages of 
apoptosis is caused by caspase-mediated cleavage of cytoskeletal components 5. Moreover, 
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caspase processing of the actin-stabilising protein Rho-associated coiled-coil-containing 
protein kinase I (ROCK I) is presumed to be involved in membrane blebbing of the apoptotic 
cell 54, 55. Further, caspases cleave the inhibitor of caspase-activated DNAse (ICAD), thereby 
releasing the active nuclease caspase-activated DNAse (CAD) which translocates to the 
nucleus and starts DNA fragmentation 56-58. Moreover, caspase-activity mediates exposure of 
PS and other engulfment signals to the cell surface as well as the fragmentation of the Golgi 
apparatus and the endoplasmic reticulum (ER) 5, 53. Thus, caspase activity is crucial for 
apoptosis. 
1.2.2. The extrinsic pathway of apoptosis 
The extrinsic pathway of apoptosis is also called death receptor-mediated apoptosis. Death 
receptors belong to the tumour necrosis factor (TNF) receptor superfamily 59. Six human 
death receptors have been identified, namely CD95 (Fas/ Apo-1), TNF-R1 (CD120a), TNF-
related apoptosis-inducing ligand receptor 1 (TRAIL-R1; DR4/Apo-2), TRAIL-R2 (DR5/ 
KILLER/TRICK-2), DR3 (Apo-3/WSL/TRAMP/LARD) and DR6 (Figure 3). Orthologues of 
all the human death receptors are found in mice, except TRAIL-R1 and TRAIL-R2 where a 
single orthologue for both receptors, TRAIL-R2, exists in mice 60, 61. The death receptors 
consist of up to six extracellular cysteine-rich domains with high sequence similarity between 
the receptors 62. Moreover, an intracellular 80-amino acid motif called the death domain (DD) 
is characteristic for the death receptors 59, 63, 64. This domain is important for transducing 
signals upon activation by the respective death ligand 59, 63, 64. Additionally, there are decoy 
receptors (DcRs) which lack the DD and therefore cannot transduce signals. These receptors 
compete with the death receptors for ligand binding. Decoy receptors for TRAIL are DcR1, 
DcR2 and Osteoprotegerin (OPG), whereas DcR3 is a decoy receptor for CD95L (Figure 3). 
The decoy receptors are presumably expressed to regulate the response to death ligands 62.  
The death receptors CD95 and TRAIL-R1/2 are activated upon binding of the death ligands 
CD95L and TRAIL, respectively, resulting in receptor oligomerisation and activation of the 
intracellular DDs 65-67. The adaptor protein Fas-associated death domain (FADD) is recruited 
via its C-terminal DD and can in turn recruit procaspase-8 via its N-terminal DED domain 68-
70
. The assembled signalling platform is called the death-inducing signalling complex 
(DISC) 70. TNF-R1 require association with the adaptor protein TNFR-associated death 
domain (TRADD) in order to recruit FADD and caspase-8 71. Humans express caspase-10 
next to caspase-8 72, 73. This protein is similar to caspase-8 and DISC-recruitment is facilitated 
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by its DED-domains 72, 73. DISC-binding of procaspases 8 and 10 bring the proteins into close 
proximity which results in dimerisation, activation and autoproteolytical cleavage 50, 51. Active 
caspase-8 and -10 process caspase-3, -6 and 7, thereby activating these effector caspases 71. 
The active effector caspases cleave numerous substrates which results in apoptosis (Figure 5) 
41, 53
.  
 
 
Figure 3. Death receptors and their ligands. The death and decoy receptors are illustrated at the bottom, 
with the extracellular cysteine-rich domains in blue and death domains (DDs) in red. The death ligands are 
shown at the top. TNF-α and LT-α/LT-β bind to TNF-R1 and TNF-R2 71. The ligand for the CD95 
receptor and DcR3 is CD95L 60. Apo3L only binds the receptor DR3, whereas TRAIL interacts with 
TRAIL-R1, TRAIL-R2, DcR1, DcR2 and OPG 60. β-amyloid precursor protein (APP) binds to DR6 74. 
Adapted from Igney and Krammer, 2002 60. 
 
1.2.3. The intrinsic pathway of apoptosis 
The intrinsic pathway of apoptosis is induced by developmental cues or cellular stress, such as 
cytokine deprivation, DNA damage, UV radiation, elevated ROS production, low ATP levels 
or pH alterations 75. This pathway is tightly regulated by the B cell lymphoma-2 (Bcl-2) 
protein family 76. Bcl-2 was discovered as an oncogene in B cell follicular lymphomas 77-79. In 
contrast to previously identified oncogenes, Bcl-2 promotes cell survival but not cell 
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proliferation 80. Since these early findings, a whole family of anti- and pro-apoptotic Bcl-2 
proteins have been identified and characterised.  
The proteins in the Bcl-2 family share Bcl-2 homology (BH) domains 81. They are divided 
into three groups according to their function and number of BH domains 81. The first group 
contains the anti-apoptotic proteins Bcl-2, Bcl-2-like protein 2 (Bcl-w), Bcl-lymphoma-extra 
large (Bcl-xL), myeloid cell leukaemia 1 (Mcl-1) and Bcl-2-related protein A1 (A1). All of 
these proteins have four BH domains (BH1-4). The pro-apoptotic proteins Bcl-2-associated x 
protein (Bax), Bcl-2 antagonist killer 1 (Bak) and Bcl-2-related ovarian killer (Bok) contain 
BH domains 1-3 and belong to the second group. The last group consists of the BH3-only 
proteins which, as the name says, only contain the BH3 domain. The proteins included in this 
group are Bcl-2 antagonist of cell death (Bad), Bcl-2-interacting killer (Bik), Bcl-2 interacting 
domain death agonist (Bid), Harakiri (Hrk, also known as death protein 5; DP5), Bcl-2-
interacting mediator of cell death (Bim), Bcl-2 modifying factor (Bmf), Noxa, p53-
upregulated modulator of apoptosis (Puma) and Mcl-1 ubiquitin ligase E3 (Mule) 76, 81 (Figure 
4A). 
 
  
Figure 4. The Bcl-2 family proteins. (A) The proteins are divided into the anti-apoptotic Bcl-2 
homologues, the effector proteins and the pro-apoptotic BH3-only proteins. (B) The BH3-only proteins 
have different binding specificities for the anti-apototic Bcl-2 proteins. tBid, Bim and Puma can bind all 
Bcl-2 homologues, whereas Bad selectively bind Bcl-2, Bcl-xL and Bcl-w, and Noxa only binds A1 and 
Mcl-1. The transmembrane domain (TM) is important for membrane integration. Adapted from Youle and 
Strasser, 2008 76. 
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Proteins of the Bcl-2 family regulate the integrity of the outer mitochondrial membrane. 
Activation of the effector proteins Bax and Bak leads to insertion of the proteins into the outer 
mitochondrial membrane, homo-oligomerisation and mitochondrial outer membrane 
permeabilisation (MOMP) 82. Stress-induced apoptosis requires one of the Bax or Bak 
proteins. Mice deficient for either Bax or Bak are healthy with minimal phenotypes, whereas 
most mice with both Bax and Bak deficiency die perinatally, with only a low percentage 
surviving to adult animals 83, 84. There is not much known about the third protein of this 
group, Bok, but it does not seem to be as important as Bax and Bak for stress-induced 
apoptosis 81. Mice with Bok deficiency appeared healthy and were fertile 85. 
The anti-apoptotic Bcl-2 family members can be integrated into the membranes of 
mitochondria, ER and nuclear envelope by their C-terminal transmembrane domain (TM) 86. 
Bcl-2 is always membrane-localised, whereas Bcl-w and Bcl-xL are directed to membranes 
after a cytotoxic signal 86. Bcl-2 and the other proteins of this group inhibit apoptosis by direct 
binding to Bax and Bak and thereby inhibiting their pro-apoptotic activities 81, 87, 88. As the 
cell senses apoptotic signals, BH3-only proteins are transcriptionally induced or activated by 
post-translational modifications 76. The BH3-only proteins act upstream of Bax and Bak, since 
apoptosis cannot be induced by BH3-only proteins without these effector proteins 84. The pro-
apoptotic activities of BH3-only proteins are primarily exerted by inhibiting the anti-apoptotic 
Bcl-2 family members 89. BH3-only proteins can bind to the hydrophobic groove in the Bcl-2 
homologues by their BH3 domain and thereby disrupting the inhibition of Bax and Bak, 
which leads to mitochondrial outer membrane permeabilisation and apoptosis 89. Truncated 
Bid (tBid), Bim and Puma bind all the anti-apoptotic Bcl-2 proteins, whereas Bad only binds 
Bcl-2, Bcl-xL and Bcl-w, and Noxa selectively binds A1 and Mcl-1 90. The ability to induce 
apoptosis is linked with the binding specificities of the BH3-only proteins; Bim and Puma 
alone can induce apoptosis, unlike Bad and Noxa where a combination of the proteins is 
required for efficient apoptosis induction 90 (Figure 4B). Consequently, mice deficient in Bad 
or Noxa are relatively healthy 91-93. In contrast, Bim is important for leukocyte homeostasis. 
Consequently, Bim deficient mice develop lymphoproliferation and autoimmune disease 94, 95. 
Puma transcription is induced by the tumour suppressor p53 in response to DNA damage 96-98. 
Mice with Puma deficiency are viable and have normal development, but Puma was shown to 
be essential in γ-radiation-induced apoptosis in the thymus and central nervous system (CNS) 
93, 99
. 
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Various stress stimuli such as DNA fragmentation, UV radiation or cytokine deprivation 
induce the intrinsic pathway of apoptosis, which results in permeabilisation of the outer 
mitochondrial membrane by the effector proteins Bax and Bak. Upon loss of mitochondrial 
membrane integrity, mitochondrial intermembrane space molecules are released to the cytosol 
including cytochrome c and second mitochondria-derived activator of caspase (Smac)/direct 
binding IAP protein with low pI (Diablo) as well as other apoptogenic factors 82. 
Cytochrome c bind to apoptotic protease-activating factor-1 (Apaf-1) and thereby induce the 
formation of the apoptosome, a signalling platform consisting of seven Apaf-1 molecules 
ordered in a wheel-like structure 100, 101. Apaf-1 is a monomer in the absence of apoptotic 
signals, but oligomerises as cytochrome c binds to its WD40 repeat domains 100, 101. 
Moreover, Apaf-1 contains a CARD domain which facilitates caspase-9 association 102. The 
monomeric form of caspase-9 is inactive, but it becomes activated as it dimerises at the 
apoptosome 103, 104. Active caspase-9 can in turn activate the executioner caspases 3 and 7, 
which cleave further death substrates and thus, inevitable cause apoptosis 105 (Figure 5). 
However, apoptosis is further controlled by x-linked inhibitor of apoptosis protein (XIAP), 
which inhibits caspase activity by direct binding to active caspase-3, -7 and -9 106. XIAP can 
in turn be inhibited by the mitochondrial proteins Smac/Diablo and Omi/HtrA2, thereby 
antagonising the inhibition of the caspases and facilitating apoptosis 107-109. Further 
apoptogenic factors released upon MOMP are the flavoprotein apoptosis-inducing factor 
(AIF) and the endonuclease G (EndoG) 110, 111. These proteins translocate to the nucleus and 
initiate large-scale DNA fragmentation (Susin 1999, Li 2001). The apoptosis-induction of AIF 
and EndoG is independent of caspases in mammalian cells, whereas upstream activation of 
the caspase homologue CED-3 is required in C. elegans for the worm AIF homologue 
(WAH-1) 112, 113. 
1.2.4. Amplification of extrinsic apoptosis signals by the intrinsic pathway 
The extrinsic and intrinsic pathways can interplay to induce apoptosis. Type I cells have 
efficient DISC-formation, which facilitates massive activation of caspase-8 and the effector 
caspases 114, 115. In contrast, type II cells have less DISC-assembly and consequently less 
activation of caspase-8. The small amount of active caspase-8 is not enough to directly 
process caspase-3, therefore an amplification of the death receptor signal via the 
mitochondrial pathway is necessary in type II cells 114, 115. The extrinsic signal is amplified by 
caspase-8-processing of the BH3-only protein Bid. The active protein truncated Bid (tBid) 
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inhibits anti-apoptotic Bcl-2 family members and consequently permeabilisation of the outer 
mitochondrial membrane by Bax and Bak can occur 116, 117. This leads to the release of 
apoptogenic molecules and ultimately apoptosis (Figure 5). The death-receptor-mediated 
apoptosis can be blocked in type II cells by overexpression of Bcl-2 or Bcl-xL, demonstrating 
the requirement of interplay between the extrinsic and intrinsic apoptosis pathways in these 
cells 114, 118. 
 
Figure 5. The extrinsic and intrinsic apoptosis pathways. The extrinsic pathway is triggered by ligand-
binding to death receptors and assembly of the DISC complex where caspase-8 is activated. Active 
caspase-8 in turn activates caspase-3 and -7. The activated effector caspases cleave further substrates, 
which results in apoptosis. c-FLIP proteins inhibit the extrinsic pathway by interfering with caspase-8 
processing. The intrinsic pathway is induced by cellular stress such as UV radiation or cytokine 
deprivation, leading to activation of the BH3-only proteins, which inhibit the anti-apoptotic Bcl-2 family 
members, thereby allowing Bax and Bak to permeabilise the outer mitochondrial membrane. Apoptogenic 
proteins from the mitochondrial intermembrane space are released to the cytosol due to the disrupted 
mitochondrial integrity. Cytochrome c (Cyt c) induces apoptosome formation and caspase-9 activation, 
which in turn activates caspase-3 and -7. Caspase-3, -7 and -9 are inhibited by XIAP, but XIAP can itself 
be inhibited by Smac/Diablo or Omi/HtrA2. Amplification of the extrinsic pathway via the intrinsic 
pathway is achieved by caspase-8-mediated cleavage of Bid to tBid, which subsequently inhibits anti-
apoptotic Bcl-2 proteins. Caspase-independent apoptosis can be induced by Omi/HtrA2 and AIF. Adapted 
from Bouillet and O’Reilly, 2009 8. 
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The apoptosis signalling in type I and type II cells differ in CD95 membrane localisation and 
internalisation. CD95 is directed to lipid rafts by post-translational palmitoylation 119, 120. 
Notably, the lipid raft localisation of CD95 receptors is more pronounced in type I than type II 
cells 121, 122. Moreover, lipid raft microdomains were reported to co-cluster with signalling 
protein oligomerisation transduction structures (SPOTS) formed at the plasma membrane 
upon CD95L-stimulation in type I cells 123. Stimulation-dependent SPOTS formation was 
observed in type II cells as well, however without lipid raft co-clustering 123. The large 
clusters formed upon triggering of the CD95 receptor are thought to be important for CD95 
internalisation and thereby apoptosis signalling in type I cells. Type II cells do not internalise 
CD95, which suggests that type I and type II cells initiate CD95 signalling in different 
ways 124, 125. 
1.3. FLICE-inhibitory proteins (FLIPs) 
Viral FLICE-inhibitory proteins (v-FLIPs) were identified through database screening for 
DED-containing proteins 126. The v-FLIP proteins are expressed in γ-herpesviruses such as 
Kaposi’s-sarcoma-associated human herpesvirus-8 (HHV8), herpesvirus saimiri and equine 
herpesvirus-2 as well as in molluscipoxviruses. Moreover, these proteins were shown to be 
inhibitors of death receptor-mediated apoptosis 126-128. 
A mammalian homologue was identified shortly thereafter, termed cellular FLIP (c-FLIP; 
also known as CASH, Casper, CLARP, FLAME-1, I-FLICE, MRIT and usurpin 129-135). The 
human CFLAR gene is localised upstream of caspase-10 and caspase-8 on chromosome 2q33-
34 131, 132, 134-138, suggesting that these genes evolved by gene duplication 135. Eleven c-FLIP 
splice variants have been reported 139, but only three of these have been identified on the 
protein level, namely c-FLIP long isoform (c-FLIPL), c-FLIP short isoform (c-FLIPS) and 
c-FLIP Raji (c-FLIPR) 118, 139-141 (Figure 6). 
c-FLIPL has the molecular weight 55 kDa and closely resembles caspase-8 (Figure 7). The 
protein has a caspase-like domain, but is catalytically inactive, since several amino acids in 
the active site have been substituted, including the catalytic residues His-237 and Cys-285 45, 
141
. The two short isoforms, c-FLIPS and c-FLIPR, mainly consist of the two DED domains 
with molecular weights of 26 kDa and 24 kDa respectively. c-FLIPS has a unique C-terminal 
tail derived from exon 7, whereas c-FLIPR has a single nucleotide polymorphism (SNP) in the 
3’ splice site of intron 6 resulting in a premature stop-codon 142 (Figure 6, Figure 7). The SNP 
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in intron 6 is functional and influences whether exon 7 is spliced or not, consequently this 
SNP determines if c-FLIPS or c-FLIPR is produced 142. The murine Cflar gene structure differs 
from the human CFLAR gene in that only c-FLIPL and c-FLIPR can be expressed 143 (Figure 
6).  
 
Figure 6. The intron-exon structure of the human and murine gene loci. Humans express c-FLIPL, c-FLIPS 
and c-FLIPR on the protein level. Exon 7, marked in green, is human-specific and gives c-FLIPS its unique 
C-terminal tail. The murine gene structure encodes for c-FLIPL and c-FLIPR. Adapted from Ueffing et al., 
2008 143. 
 
c-FLIP is expressed abundantly in many tissues, for instance in neurons, cardiac myocytes, 
epithelial cells, macrophages, T and B cells 144. The c-FLIP expression can be regulated by 
NF-κB, since various NF-κB stimuli such as TNF-α and IL-1, lipopolysaccharide (LPS) and 
CD40L for B cells as well as phorbol-12-myristate-13-acetate (PMA) and ionomycin or anti-
CD3 and anti-CD28 for T cells induce upregulation of c-FLIP expression  145, 146. Moreover, 
calcineurin-nuclear factor of activated T cells (NFAT) mediates induction of c-FLIPS in short-
term activated T cells 147. Cytokines such as IL-2, IL-4, IL-6, IL-10, IL-12 and interferon-γ 
(IFN-γ) presumably also influence c-FLIP expression in T cells 144.  
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Figure 7. Structure of c-FLIP proteins. All viral and cellular FLIP proteins contain tandem DED domains. 
c-FLIPL has a similar structure as caspase-8, but lacks catalytic activity. The short splice variants of c-FLIP 
resemble the viral FLIP proteins. c-FLIPS has a unique C-terminal tail, whereas c-FLIPR is produced in 
individuals with a SNP in the 3’ splice site of intron 6. All c-FLIP proteins can be cleaved at D198 which 
results in a p22 fragment, c-FLIPL can additionally be processed at D376 130, 148. There are two functional 
splice variants of human caspase-8, termed caspase-8/a and caspase-8/b with the molecular weight 53 and 
55 kDa respectively 42. Adapted from Budd et al., 2006 144. 
 
c-FLIP proteins regulate death receptor-mediated apoptosis by interfering with caspase-8 
activation 118, 149. Stimulation of death receptors initiates DISC assembly, resulting in 
activation and processing of caspase-8. Full cleavage of caspase-8 releases the p10 and p18 
products into the cytosol where the active enzyme is formed from two small p10 and two 
large p18 subunits 150. The DED domains of the c-FLIP proteins allow recruitment to the 
DISC 143 and therefore these proteins compete with caspase-8 for DED binding sites at the 
DISC. c-FLIP proteins also inhibit cleavage of caspase-8 149, hence the amount of active 
caspase-8 is reduced by c-FLIP and thereby the caspase cascade of apoptosis is prevented 118, 
140, 149
.  
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Figure 8. c-FLIP proteins regulate caspase-8 activity. Dimerised caspase-8 initiate activation and 
autoproteolytical cleavage of the caspase-8 molecules, which results in the active enzyme and ultimately 
apoptosis (left). Heterodimers of caspase-8 and c-FLIPL leads to activation of caspase-8, but only partial 
cleavage and therefore only limited caspase-8 activity (middle). Caspase-8 cannot be activated in 
heterodimers with c-FLIPS or c-FLIPR. Thus, cleavage does not occur and apoptosis is inhibited. Adapted 
from Krueger et al., 2001 149. 
 
c-FLIPL can activate caspase-8 via dimerisation at the DISC in contrast to c-FLIPS. This leads 
to initial processing of both caspase-8 and c-FLIP into the p41 (caspase-8/b) and p43 
(caspase-8/a and c-FLIPL) fragments, although further cleavage to fully active caspase-8 is 
inhibited 118, 149 (Figure 8). The short c-FLIP splice variants only have anti-apoptotic 
functions 140, 143, 149, in contrast to c-FLIPL where dual roles of the protein have been reported 
151, 152
. Low levels of c-FLIPL facilitate caspase-8 processing and apoptosis, whereas high 
c-FLIPL levels inhibit apoptosis 151, 152. Moreover, the strength of CD95 receptor stimulation 
also influences whether c-FLIPL acts pro- or anti-apoptotic 153. Moderate expression of 
c-FLIPL was shown to promote apoptosis only upon strong receptor stimulation or in 
combination with overexpression of c-FLIPS or c-FLIPR. In contrast, high levels of c-FLIPL 
diminished the sensitivity for CD95-induced apoptosis and caspase-8 activation 153. 
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1.4. CD95-mediated apoptosis in the immune system 
Functional CD95 receptor signalling ensures efficient removal of unwanted immune cells. Lpr 
and gld mice have defects in CD95-mediated apoptosis due to mutations in the CD95 receptor 
and ligand, respectively 154, 155. These mice develop lymphoproliferation and systemic 
autoimmunity 154, 155. Autoimmune lymphoproliferative syndrome (ALPS) was identified in 
humans as a disease resembling the murine lpr/gld phenotype 156. Indeed, the majority of 
ALPS patients have mutations in genes encoding the CD95 receptor, ligand or proteins 
involved in CD95 signalling 157. ALPS patients as well as lpr/gld mice accumulate an unusual 
population of CD3+CD4-CD8- (double negative; DN) αβ T cells in the periphery 158-161. These 
DN T cells express B220, a marker generally associated with B cells 162. Moreover, an 
elevated IL-10 production of the DN αβ T cells was observed in ALPS patients 163. The 
cytokine profile with high levels of IL-10 in conjunction with increased levels of IL-4 and 
IL-5 as well as decreased IL-2 and IFN-γ levels is characteristic for T helper type 2 (Th2) 
cells 163. Since Th2 cells support humoral immune responses, the altered cytokine milieu 
might increase autoantibody production in ALPS patients.  
The dynamics of T cell expansion and contraction is essential for the adaptive immune 
system. T cells become activated by interacting with antigen bound to major 
histocompatibility complex (MHC) together with co-stimulatory signals on antigen presenting 
cells (APCs). This induces differentiation and clonal expansion of T cells to efficiently clear 
the antigen. Most effector T cells need to be eliminated after successful antigen clearance to 
maintain the T cell homeostasis. Only few antigen-specific T cells persist as memory cells to 
ensure a rapid response upon re-encounter of the same antigen 164, 165. 
T cells can be eliminated by activation-induced cell death (AICD) or ‘death by neglect’ in the 
contraction phase of an immune response. Cytokine withdrawal induces ‘death by neglect’, 
which depends on the intrinsic pathway, whereas AICD is triggered by T cell receptor (TCR) 
restimulation of activated T cells 33. TCR restimulation induces CD95L expression and 
thereby the CD95 signalling pathway 166-169. The CD95L expression of T cells can induce 
autocrine apoptosis, but apoptosis can also be induced in neighbouring T cells, DCs and B 
cells (Figure 9) 33, 170. 
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Figure 9.  Activation-induced cell death of T cells. T cells are activated upon encounter of an antigen 
presented by APCs i.e. dendritic cells (DCs). Subsequently, T cells differentiate and clonally expand. 
CD95L expressed on T cells can induce apoptosis in B cells and DCs. Restimulation of activated T cells 
induces CD95L expression, which is an apoptosis-signal for the same or neighbouring cells. Adapted from 
Ramaswamy and Siegel, 2007 170. 
 
Resting T cells only express low levels of CD95 receptor and these cells are resistant to 
apoptosis 171, 172. CD95 expression is induced upon T cell activation 171, 172. Although both 
short- and long-term activated T cells have high CD95 expression, short-term activated T 
cells are apoptosis-resistant whereas long-term activated T cells are apoptosis-sensitive 172, 173 
(Figure 10). Due to the comparable CD95 expression, AICD must be regulated down-stream 
of the death receptor. Indeed, short-term activated T cells have high c-FLIPS expression, 
which is downregulated in long-term activated T cells 174, 175. Memory T cells are apoptosis-
resistant and express CD95 at levels comparable with short-term activated T cells 176.  
The level of DISC formation distinguishes type I from type II cells. Short-term activated T 
cells have inefficient DISC assembly and behave like type II cells 177. Additionally, these cells 
express high levels of Bcl-xL, which inhibits the mitochondrial pathway of apoptosis 177. In 
contrast, long-term activated T cells have type I-characteristics with strong DISC formation 
and are sensitive for apoptosis 177. Effector T cells secrete IL-2, which is a cytokine important 
for T cell proliferation and survival 178. However, this cytokine also appears to regulate the 
elimination of T cells during the deletion phase of an immune response, since mice with IL-2 
or IL-2 receptor deficiency accumulate activated T cells and develop autoimmunity 179-181. 
Interestingly, long-term activated T cells cultured in the absence of IL-2 were considerably 
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less sensitive towards AICD 177. This suggests that the switch from the apoptosis-resistant 
type II phenotype of short-term activated T cells to the apoptosis-sensitive type I 
characteristics of long-term activated T cells depends on IL-2.  
 
 
Figure 10. Naïve T cells express low levels of CD95 and are resistant to apoptosis. T cells become 
activated as they encounter an antigen, which leads to differentiation into effector T cells and clonal 
expansion. These T cells express high levels of CD95, but are resistant to apoptosis due to high c-FLIPS 
expression. The deletion phase begins when all antigen is removed. Down-regulation of c-FLIP sensitises T 
cells for AICD. Only few cells persist as memory cells to ensure a rapid immune response upon re-
encounter of the same antigen. Memory T cells are apoptosis-resistant, although the expression level of 
CD95 is comparable to short-term activated T cells. Adapted from Krueger et al., 2003 165. 
 
The BH3-only protein Bim is also important for the shut-down of an immune response by 
sensing cytokine withdrawal and activating the intrinsic pathway 94. Mice deficient in Bim 
and with mutated CD95 show drastic lymphoproliferation and rapidly develop severe 
autoimmunity, which suggests that Bim and CD95 cooperate to eliminate effector T cells in 
the deletion phase 182-184. It is anticipated that Bim ensures deletion of T cells which received 
a strong antigen signal as for instance in an acute viral infection. In contrast, CD95 signalling 
is presumed to be more important in removal of the weakly stimulated T cells in chronic viral 
infections 182-184. 
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CD95-mediated apoptosis is also critical in the elimination of antigen presenting cells. Naïve 
B cells only express very low levels of CD95, but the receptor is upregulated upon activation 
by e.g. CD40L 185. Like T cells, B cells upregulate anti-apoptotic proteins upon activation to 
resist apoptosis, with c-FLIP playing an important role in the apoptosis-resistance 186. Mice 
with CD95 deficiency in dendritic cells (DCs) or B cells develop systemic autoimmunity 187. 
Clearly, the antigen-presenting cells need to be deleted to prevent accumulation of 
autoreactive B cells and chronically activated autoimmune T cells. 
1.5. The role of death receptors and c-FLIP in cancer 
Defects in the apoptosis machinery can lead to uncontrolled growth and tumour formation 60. 
Notably, high levels of c-FLIP proteins have been identified in various cancer types 188, 
prominently Hodgkin’s lymphoma 189, 190 and melanoma 141, 191. The upregulation of c-FLIP 
and other anti-apoptotic proteins is a mechanism for tumours to avoid apoptosis and evade 
immune surveillance 188, 192, 193. Moreover, upregulation of c-FLIP has been suggested as a 
possible mechanism for resistance to therapeutic triggering of death receptors and the 
extrinsic apoptotic pathway, which is studied as a promising approach to cancer therapy. 
Current research apply genetic engineering to specifically direct the death ligands to tumour 
cells in order to circumvent the life-threatening side effects of systemic administration of TNF 
and CD95L 194. In contrast to TNF and CD95L, TRAIL was reported to selectively induce 
apoptosis in various tumour cells in vivo without affecting cells in normal tissues 195, 196. 
However, more recent studies described resistance against TRAIL-induced apoptosis in many 
primary tumour cells 197. Upregulation of decoy receptors in tumour cells is a further proposed 
resistance-mechanism of cancer cells 198. The decoy receptor DcR3 can bind CD95L, likewise 
is TRAIL interacting with DcR1 and DcR2 71. However, it is still under debate whether decoy 
receptors can mediate tumour-resistance or not 198. Interestingly, CD95 signalling also exerts 
non-apoptotic functions in tumour cells. Tumour growth is promoted by CD95 signalling 199. 
Moreover, CD95 signalling induced invasiveness and motility, especially in apoptosis-
resistant tumours 200. These non-apoptotic functions of CD95 require activation of the NF-κB 
and mitogen-activated protein (MAP) kinase signalling pathways 199, 200. 
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1.6. Non-apoptotic functions of c-FLIP 
Proteins interacting at the death-inducing signalling complex (DISC) have additional 
functions apart from apoptosis-regulation. Complete knock-out of one of the proteins FADD, 
caspase-8 or c-FLIP results in embryonic lethality due to defects in vascularisation of the yolk 
sac and cardiac failure 201-203, which clearly indicates that these proteins are crucial in 
embryonic development. FADD, c-FLIPL and caspase-8 have further non-apoptotic functions. 
Interestingly, these proteins have been reported to activate the NF-κB pathway 204-207. 
However, it is not clear how c-FLIPL induces NF-κB activation. Kataoka and co-workers 
reported that overexpression of c-FLIPL in Jurkat cells lead to activation of NF-κB and the 
MAP kinase ERK as wells as increased IL-2 production upon stimulation 206. The activation 
of NF-κB was explained by recruitment of TNFR-associated factor 2 (TRAF2) and receptor-
interacting protein 1 (RIP1) to the CD95 DISC by the p43 product of c-FLIPL (c-FLIP(p43)), 
which is a fragment arising from caspase-8 processing. Inhibition of caspase-8 blocked 
NF-κB activation induced by full-length c-FLIPL but not by c-FLIP(p43) 206-208, suggesting 
that caspase-8 cleavage is necessary for the c-FLIPL-dependent NF-κB activation. Notably, 
Golks and colleagues reported cytoplasmic caspase-8 processing of c-FLIP proteins at D198, 
which results in a p22 fragment (p22-FLIP) consisting of the tandem DED domains 148. p22-
FLIP was observed to directly interact with the IκB kinase (IKK) complex and thereby induce 
NF-κB activation 148. In contrast, effector T cells from mice overexpressing human c-FLIPS 
were reported to have reduced NF-κB activation 209. Further investigation is necessary to 
clarify the role of c-FLIP proteins in NF-κB activation. 
Caspase activity is required for T cell activation 210, 211 and mutations leading to inactive 
caspase-8 were shown to result in defects in lymphocyte activation both in mice 212 and 
men 213. Caspase-8 deficiency is not lethal in humans in contrast to mice. This is probably due 
to the presence of caspase-10 in humans, which at least in part has the same function as 
caspase-8, whereas mice lack caspase-10 214. Similar to caspase-8, c-FLIPL is important for T 
cell activation. Lens and colleagues reported increased proliferation in T cells from c-FLIPL 
transgenic mice upon stimulation with suboptimal doses of anti-CD3 215. Likewise, Dohrman 
and co-workers showed increased proliferation and IL-2 responsiveness upon antigen 
stimulation of CD8+ T cells from c-FLIPL transgenic mice, due to high CD25 expression 208. 
Moreover, mice with T cell-specific c-FLIP deficiency had decreased IL-2 production and 
defective IL-2 responsiveness 216, 217. Similar effects were observed in T cells both from mice 
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deficient in FADD or with dominant negative FADD expression 203, 218, 219 as well as mice 
with caspase-8 deficiency 212. Additionally, T cell development was disturbed in mice with T 
cell-specific c-FLIP deficiency. Although mature lymphocytes developed in these mice, the 
numbers were severely reduced 216, 217. Especially c-FLIPL was reported to play a central role 
in T cell proliferation. However, Zhang et al. showed that TCR stimulation induced normal 
activation of NF-κB and MAP kinase pathways in c-FLIPL-/- mice 220, which indicates that 
c-FLIPL mediates T cell proliferation independently of the NF-κB pathway. 
Besides its function as an apoptosis-regulator, c-FLIP also regulates autophagy, a process 
where cytoplasmic components are recycled or removed. LC3 is a protein involved in 
autophagosome formation and becomes conjugated to the lipid phosphatidylethanolamine 
(PE) during this process 29. The PE-binding of LC3 is catalysed by autophagy-related 
protein 3 (Atg3) 29 and c-FLIP proteins can inhibit autophagy by competing with LC3 for 
Atg3-binding 221, 222. 
Interestingly, the embryonic lethality of FADD-deficient mice was partially rescued by RIP1 
deficiency 223 and the double knock-out of FADD and RIP3 completely rescued the 
embryonic development 224. Likewise, the embryonic lethality of caspase-8-deficient mice 
was rescued by RIP3 deficiency 225. The kinase activity of RIP1 and RIP3 is required for the 
cell death mode called necroptosis 226. These kinases can be activated at complex IIb (also 
called the necrosome), which is formed upon TNF receptor stimulation or at the ripoptosome, 
which is assembled in response to double-stranded RNA or genotoxic stress 28. Caspase-8 can 
inhibit necroptosis by processing of RIP1 and RIP3 28. Notably, caspase-8 requires c-FLIPL 
heterodimerisation for catalytical activation and inhibition of RIP3-dependent necrosis 227. 
These findings reveal a fine-tuned balance between apoptosis and necroptosis during the 
embryonic development, regulated by c-FLIP proteins.  
Taken together, c-FLIP proteins are crucial regulators of life and death decisions in the cell. 
Further investigations are necessary to reveal the exact molecular mechanisms behind these 
decisions.
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1.7.  Aim of the thesis 
c-FLIP proteins play a central role in the regulation of death receptor-mediated apoptosis. 
Caspase-8 activation is inhibited by c-FLIP proteins at the level of death receptors and 
thereby the apoptosis-signalling is disturbed 118, 140, 149. There is a strict control of cell 
elimination and cell survival. Different diseases can develop if apoptosis is deregulated. 
Insufficient apoptosis may lead to tumour formation or autoimmunity, whereas 
immunodeficiency is a result of excessive apoptosis. The proteins interacting at the DISC 
complex are not only important regulators of apoptosis. c-FLIPL, caspase-8 and FADD have 
also been reported as activators of NF-κB signalling 204, 206-208. Moreover, c-FLIP proteins 
were reported to regulate necroptosis and autophagy 28, 221, 222. The aim of this thesis is to gain 
a better understanding of c-FLIP proteins’ role in disease and to examine if there are unknown 
DISC-interacting proteins which could give a better insight into the complex signalling of the 
CD95 receptor. The three projects of this thesis are described below. 
• c-FLIP proteins are often up-regulated in tumour cells as a mechanism to avoid 
apoptosis and to escape immune surveillance 60. Moreover, high levels of c-FLIP can 
lead to resistance to therapeutics targeting death receptor-mediated apoptosis. Cancer 
of the urinary bladder is one of the most common cancers in the United States of 
America and Europe. The high morbidity and mortality of bladder cancers urge for 
improved treatment strategies and for understanding the mechanisms underlying 
resistance to immunotherapy and chemotherapy. For these reasons, the function of 
c-FLIPL and c-FLIPS isoforms in apoptosis-resistance of urothelial carcinoma was 
examined. 
• DISC-interacting proteins not only have apoptotic functions, but have also been 
implicated in NF-κB signalling, proliferation and T cell activation. However, the exact 
signalling mechanisms are not fully understood. Moreover, the concept of the DISC 
model was questioned recently, since chain formation of DED-proteins at the DISC 
was revealed 228, 229. The CD95 DISC and the influence of c-FLIPL on the complex 
was studied in this thesis to possibly identify novel interaction partners and gain 
further insight into the signalling pathways of death receptors.    
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• c-FLIPR is the only short isoform of c-FLIP expressed in mice. Nevertheless, it is so 
far unclear if c-FLIPR is expressed on the protein level and if so, the function of the 
protein remains to be investigated. c-FLIP proteins play an important role in immune 
cells and high expression levels are observed in activated T and B cells to protect these 
cells from apoptosis 174, 186. The role of murine c-FLIPR in the immune system was 
investigated by using a mouse model with transgenic expression of murine c-FLIPR in 
all hematopoietic compartments. 
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2. Materials 
2.1. Chemicals 
Chemicals were purchased from Sigma Aldrich (Munich, Germany) or Roth (Karlsruhe, 
Germany) if not stated otherwise. 
2.2. Materials and reagents for cloning 
DNA for cloning was amplified by the proof-reading polymerase PhusionTM Flash 
(Finnzymes – Thermo Scientific, Vantaa, Finland) in peqSTAR 96 universal thermocyclers 
(PEQLAB Biotechnologie, Erlangen, Germany). Cleavage of vectors and inserts was 
performed with restriction enzymes from New England Biolabs (Ipswich, MA, USA), see 
2.2.1. Cleaved vectors were ligated with the respective inserts by using T4 DNA ligase from 
New England Biolabs. Constructs were transformed into Escherichia coli (E. coli) strain 
Top10 (Life technologies, Grand Island, NY, USA) for amplification of plasmids. Bacteria 
were grown in LB-medium (1% w/v tryptone, 0.5% w/v yeast extract, 85.6 mM NaCl, 1 mM 
NaOH). Absorbance at 260 nm and 280 nm was measured by NANODROP 1000 
spectrophotometer (PEQLAB) to determine the concentration of isolated DNA. 
2.2.1. Restriction enzymes 
Restriction enzyme Recognition site Incubation temp.
Bam HI 5'...G│GATCC…3' 37 °C
3'...CCTAG│G…5'
Nco I 5'...C│CATGG…3' 37 °C
3'...GGTAC│C…5'
Nhe I 5'...G│CTAGC…3' 37 °C
3'...CGATC│G…5'
Sma I 5'...CCC│GGG…3' 25 °C
3'...GGG│CCC…5'
Xba I 5'...T│CTAGA…3' 37 °C
3'...AGATC│T…5'
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2.3. DNA gel electrophoresis 
DNA was separated by gel electrophoresis in Perfect BlueTM Gel System (PEQLAB). 
Ethidium bromide containing gels were documented in a gel documentation system (INTAS 
science imaging, Goettingen, Germany). 
2.4. Cell culture materials and devices 
Cells were cultured in cell culture flasks, 10 cm dishes, 6-well, 12-well, 24-well or 96-well 
plates from NUNC – Thermo Scientific (Waltham, MA, USA)  in the incubator HERAcell 
240 i (Thermo scientific) at 37°C, 5% CO2 and 95% air humidity. Materials used for handling 
of cells were: 1.5 ml and 2 ml reaction tubes (Sarstedt, Nuembrecht, Germany), sterile 10 µl, 
200 µl and 1000 µl pipette tips (Starlab, Ahrensburg, Germany), 5 ml, 10 ml and 25 ml 
pipettes (Sterilin - Thermo Scientific), 15 ml and 50 ml reaction tubes (Greiner-bio-one, 
Frickenhausen, Germany), 45 µm and 22 µm sterile syringe filters (Merck Millipore, 
Billerica, MA, USA). Centrifuges used were 5810R from Eppendorf (Hamburg, Germany) 
and Megafuge 1.0 from Heraeus SEPATECH (Osterode, Germany). Cells were handled in 
sterile hoods SterilGARD® III Advance° (The Baker Company, Sanford, ME, USA). Cell 
numbers were determined by Neubauer improved cell counting chambers (BRAND scientific, 
Wertheim, Germany) or CellometerTM Auto T4 (Nexcelom Bioscience, Lawrence, MA, 
USA). 
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2.4.1. Cell culture reagents  
Medium / supplement Cat. No. Company
DMEM (high glucose) 11965 Gibco®- Life technologies 
IMDM 11875 Gibco®- Life technologies
RPMI 1640 12440 Gibco®- Life technologies
Fetal calf serum (FCS)
(Lot. No. A 10108-2367) A15-101 PAA (Pashing, Austria)
Sodium-pyruvate 100 mM 11360-070 Gibco®- Life technologies
Non-essential amino acids 100x 11140 Gibco®- Life technologies
Penicillin / streptomycin 15070 Gibco®- Life technologies
β-mercaptoethanol 50 mM 21985-023 Gibco®- Life technologies
0.05% Trypsin/ EDTA 25300 Gibco®- Life technologies
Puromycin P8833 Sigma Aldrich
G418 A 2912 Biochrom (Berlin, Germany)
 
2.4.2. Reagents and antibodies used for stimulation of cells 
Reagent / antibody Clone/ Cat. No. Reactivity Company
 notation
anti-CD3 145-2C11 - ms self purified
anti-CD3 145-2C11 100331 ms BioLegend
(San Diego, CA, USA)
anti-CD28 E18 - ms self purified
anti-CD28 37.51 102112 ms BioLegend
Concanavalin A - C2010 hu, ms Sigma Aldrich
murine interleukin-2 - 402-ML ms R&D Systems
(Minneapolis, MN, USA)
Phorbol 12-myristate
13-acetate (PMA) - P8139 hu, ms Sigma Aldrich
Ionomycin (iono) - I-0634 hu, ms Sigma Aldrich
CD95 2R2 - hu self purified
CD95 Jo2 554255 ms BD Biosciences 
(Heidelberg, Germany)
CD95L scErbB2 - hu, ms self purified
TRAIL - 810904 hu Novitec 
(Freiburg im Breisgau, Germany)
QVD - OPh - OPH109 hu, ms MP Biomedicals
(Aurora, OH, USA)
Protein A from S. aureus - 6031 hu, ms Sigma Aldrich
LPS from E.coli - L4516 hu, ms Sigma Aldrich
 
The reactivity against mouse (ms) or human (hu) is shown. 
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2.5. Cell lines 
HEK293T cells 230-234 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) high 
glucose supplemented with 10% FCS and 50 µg/ml of penicillin and streptomycin. The 
parental urothelial cell lines VMCub1 235 and SD 236 were cultured in DMEM high glucose 
supplemented with FCS, penicillin and streptomycin as above. VMCub1 and SD cell lines 
stably transduced with shRNAs targeting a scramble sequence, c-FLIPL, c-FLIPS or both 
isoforms (c-FLIPL/S) 237 were cultured in DMEM high glucose with supplements as above. 
Jurkat E6.1 cells 238, 239 were cultured in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with FCS, penicillin and streptomycin as above. 
2.6. Mouse strain  
The mouse strain vavFLIPR was generated by the transgenic core facility of the University of 
Duesseldorf, Germany from a transgenic construct with murine c-FLIPR cDNA in the vector 
HS21/45 vav-hCD4 240. Mice carrying the transgenic construct were backcrossed for more 
than ten generations to C57BL/6 mice. WT littermates were used as control animals. 
Genotyping was performed by PCR on tail biopsies using KAPA Mouse Genotyping Hot 
Start Kit (PEQLAB) according to manufacturer’s protocol. All of the animals were kept under 
specific pathogen free (SPF) conditions in the animal facilities of the Helmholtz Centre for 
Infection Research, Brunswick, Germany. All breeding and experiments were performed in 
accordance with the guidelines of national and local authorities.  
2.7. Western blotting materials and reagents 
Protein concentrations were determined by bicinchoninic acid (BCA) assay following 
manufacturer’s instructions (Pierce Protein Research Products – Thermo Scientific, Rockford, 
IL, USA). The BCA assay was measured at 562 nm in the Infinite® M200 microplate-reader 
(TECAN, Maennedorf, Switzerland). Gel electrophoresis and protein transfer was performed 
in devices purchased from BioRad Laboratories (Hercules, USA). Western blots were 
developed with a chemiluminiscent reagent in the Fusion FX-7 camera (Vilber Lourmat, 
Eberhardzell, Germany). 
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2.7.1. Primary antibodies 
Antibody Clone/ Reactivity Isotype Species Company
notation
A20 A-12 hu IgG2a mouse Santa Cruz Biotechnology
(Santa Cruz, CA, USA)
β-actin AC-74 ms, hu IgG2a mouse Sigma Aldrich
Bcl-2 C-2 hu, ms, rt IgG1 mouse Santa Cruz Biotechnology
caspase-3 AF-605-NA hu IgG goat R&D Systems
cleaved caspase-3 5A1E hu, ms, rt, mk IgG rabbit Cell Signaling Technology
(Asp175) (Danvers, MA, USA)
caspase-8 1G12 ms IgG rat Enzo Life Sciences
(Loerrach, Germany)
caspase-8 12F5 hu IgG2b mouse gift from Dr. K. Schulze-Osthoff
(Tuebingen, Germany)
caspase-9 #9502 hu IgG rabbit Cell Signaling Technology
CD95 / Fas C-20 hu IgG rabbit Santa Cruz Biotechnology
c-FLIP Dave-2 hu, ms IgG rat Enzo Life Sciences
c-FLIP Dave-2 hu, ms IgG rat Adipogen (San Diego, CA, USA)
c-FLIP NF6 hu IgG1 mouse Enzo Life Sciences
FADD 1F7 hu, ms IgG1 mouse Merck Millipore
IKKα B-8 hu, ms, rt IgG2b mouse Santa Cruz Biotechnology
IKKγ FL-419 hu, ms, rt IgG rabbit Santa Cruz Biotechnology
IκBα 112B2 hu, ms, rt, mk IgG2a mouse Cell Signaling Technology
p-IκBα (Ser32) 14D4 hu, ms, rt, mk IgG rabbit Cell Signaling Technology
RIP 38 hu IgG2a mouse BD Biosciences
TRAF-2 C90-481 hu IgG2a mouse BD Biosciences
α-tubulin DM-1A hu, ms IgG1 mouse Sigma Aldrich
XIAP 48 hu, ms, rt IgG1 mouse BD Biosciences
FLAG®-tag M2 - IgG1 mouse Sigma Aldrich
HA-tag 12CA5 - IgG2b mouse Roche 
(Grenzach - Wyhlen, Germany)
 
The reactivity against human (hu), mouse (ms), rat (rt) or monkey (mk) is shown. 
 
2.7.2. Horseradish peroxidase conjugated secondary antibodies  
Reactivity Species Cat. No Company
mouse IgG goat sc-2031 Santa Cruz Biotechnology
mouse IgG1 goat 1070-05 Southern Biotechnology
(Birmingham, AL, USA)
mouse IgG2a goat 1080-05 Southern Biotechnology
mouse IgG2b goat 1090-05 Southern Biotechnology
goat IgG rabbit 6165-05 Southern Biotechnology
rabbit IgG goat 4030-05 Southern Biotechnology
rat IgG goat 3050-05 Southern Biotechnology
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2.8. Materials and reagents for flow cytometry 
2.8.1. Flow cytometry devices 
Fluorescently labelled cells were analysed in FACS Calibur, FACS Canto or LSRII (BD 
Biosciences). Sorting of cells was performed in an FACS Aria II (BD Biosciences) or MoFlo 
(Beckham Coulter, Indianapolis, IN, USA). Data was analysed by the FlowJo software 
(TreeStar, Ashland, OR, USA). 
 
2.8.2. Fluorescent dyes 
Reagent Excitation Emission Company
LIVE/DEAD®
Near IR flurescent reactive dye 750 nm 775 nm Life technologies
LIVE/DEAD®
Blue fluorescent reactive dye 350 nm 450 nm Life technologies
Tetramethylrhodamine ethyl ester
(TMRE) 549 nm 574 nm Enzo Life Sciences
7-amino-actinomycin D (7AAD) 543 nm 647 nm BD Biosciences
 
 
2.8.3. Human antibodies 
Reactivity Fluorochrome Clone/ notation Isotype Company
CD95 - 2R2 mouse IgG3 self-made
TRAIL-R1 (DR4) - HS101 mouse IgG1 Enzo Life Sciences
TRAIL-R2 (DR5) PE DJR2-4 mouse IgG1, κ eBioscience
TNF-R1 - H398 mouse IgG2a gift of Dr. H. Wajant,
Wuerzburg, Germany
CD3 Alexa Fluor® 647 HIT3a rat IgG2a, κ BioLegend
CD4 Pacific blue RPA-T4 mouse IgG1, κ BioLegend
CD8 PerCP Cy5.5 HIT8a mouse IgG1, κ BioLegend
CD25 PE BC96 mouse IgG1, κ BioLegend
CD69 APC Cy7 FN50 mouse IgG1, κ BioLegend
Active caspase-3 Horizon V450 C92-605 rabbit IgG BD Biosciences
 
TNF-R1, TRAIL-R1 and CD95 antibodies were labelled with PE-conjugated goat-anti-mouse 
secondary antibody (Jackson ImmunoResearch, Suffolk, UK). 
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2.8.4. Murine antibodies  
Reactivity Fluorochrome Clone/ notation Isotype Company
CD3 eF450 17A2 rat IgG2b, κ eBioscience
(San Diego, CA, USA)
CD3 FITC 145-2C11 hamster IgG1, κ BD Biosciences
CD4 Pacific blue RM4-5 rat IgG2a, κ BioLegend
CD4 Horizon V500 RM4-5 rat IgG2a, κ BD Biosciences
CD8 APC 53-6.7 rat IgG2a, κ Biolegend
CD8 FITC 53-6.7 rat IgG2a, κ BD Biosciences
CD11b PE Cy7 M1/70 rat IgG2b, κ eBioscience
CD11c APC eFluor 780 N418 hamster IgG eBioscience
CD19 PerCP Cy5.5 1D3 rat IgG2a, κ eBioscience
CD19 FITC 1D3 rat IgG2a, κ BD Biosciences
CD25 PE Cy7 PC61.5 rat IgG1, λ BD Biosciences
CD44 PE IM7 rat IgG2b, κ eBioscience
CD45R (B220) APC RA3-6B2 rat IgG2a, κ eBioscience
CD49b APC Dx5 rat IgM, κ eBioscience
CD62L PerCP Cy5.5 MEL-14 rat IgG2a, κ eBioscience
CD95 PE Jo-2 hamster IgG2, λ2 BD Biosciences
F4/80 PE BM8 rat IgG2a, κ eBioscience
Gr1 Pacific blue RB6-8C5 rat IgG2b, κ eBioscience
AnnexinV APC - - BD Biosciences  
 
2.9. Oligonucleotides 
Salt free, HPSF or HPLC purified, lyophilised oligonucleotides were purchased from Eurofins 
MWG Operon (Ebersberg, Germany).  
Cloning c-FLIP isoforms into the vector pIRES2-EGFP
Sequence (5' → 3')
5' c-FLIP fwd GGC TAG CCA TGT CTG CTG AAG TCA TCC A
3' c-FLIPL rev GCC CGG GCT TAT GTG TAG GAG AGG ATA A
3' c-FLIPR rev GCC CGG GCT CAT GCT GGG ATT CCA TAT G
3' c-FLIPS rev GCC CGG GCT CAC ATG GAA CAA TTT CCA A
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Attaching HA-tag to c-FLIPL and cloning into the vector pEF/myc/cyto
Sequence (5' → 3')
HA-tag oligo fwd GCA CCA TGG CCT ACC CAT ACG ACG TGC CTG
ACT ACG CCT CTG CTG AAG TCA TCC ATC A
HA-tag oligo rev TGA TGG ATG ACT TCA GCA GAG GCG TAG TCA
GGC ACG TCG TAT GGG TAG GCC ATG GTG C
c-FLIPL HA-tag fwd ACG ACG TGC CTG ACT ACG CCT CTG CTG AAG
TCA TCC ATC AGG TTG
c-FLIPL HA-tag rev CTA TCT AGA TTA TGT GTA GGA GAG GAT AAG
TTT CT 
HA-tag fwd GCA CCA TGG CCT ACC CAT ACG AC
Quantitative
RT PCR Sequence (5' → 3')
c-FLIPL fwd CCT AGG AAT CTG CCT GAT AAT CGA
c-FLIPL rev TGG GAT ATA CCA TGC ATA CTG AGA TG
c-FLIPS fwd GCA GCA ATC CAA AAG AGT CTC A
c-FLIPS rev ATT TCC AAG AAT TTT CAG ATC AGG A
GAPDH fwd ATC ACC ATC TTC CAG GAG CGA GAT C
GAPDH rev GGC AGA GAT GAT GAC CCT TTT GGC
TBP fwd CGA AAC GCC GAA TAT AAT CC
TBP rev CGT GGC TCT CTT ATC CTC A
Sequencing Sequence (5' → 3')
c-FLIPL fwd seq TGG GAG AAG TAA AGA ACA AAG AC
c-FLIPL rev seq AAG TGA AGG TGT CTC GAA GAA
CMV fwd CGC AAA TGG GCG GTA GGC GTG
EF1alpha fwd TCT CAA GCC TCA GAC AGT GGT TC
pCR3.1-BGH rev TAG AAG GCA CAG TCG AGG
T7 TAA TAC GAC TCA CTA TAG GG
T3  AAT TAA CCC TCA CTA AAG GG 
Genotyping Sequence (5' → 3')
c-FLIP fwd GCC TGA AGA ACA TCC ACA GAA TAG
SV40 poly A rev CTC ATC AAT GTA TCT TAT CAT GTC
β-actin fwd TGT TAC CAA CTG GGA CGA CA
β-actin rev TCT CAG CTG TGG TGG TGA AG
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2.10. Frequently used buffers 
Group Buffer Contents
Flow cytometry buffers PBS 155.17 mM NaCl
2.97 mM Na2HPO4
1.06 mM K2HPO4
pH 7.4
FACS buffer 2% w/v BSA in PBS
0.01% v/v NaN3
10x annexinV binding buffer 0.1 mM HEPES / NaOH
1.4M NaCl
25 mM CaCl2
pH 7.4
Nicoletti buffer 0.1% v/v Triton X-100
0.1% C6H5Na3O7
50µg/ml PI
Lysis buffers and TPNE lysis buffer PBS
additives ad 300 mM NaCl
2mM EDTA 
1% v/v Triton X-100
DISC lysis buffer 30 mM Tris/HCl
150 mM NaCl
10% v/v glycerol
1% v/v Triton X-100
2 mM EDTA
10mM NaF
pH 7.4
100x protease inhibitors 100 µg/ml aprotinin
100 µg/ml leupeptin
100 µg/ml pepstatin A
100 µg /ml chymostatin
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Group Buffer Contents
Western blot buffers 5x reducing sample buffer 50 mM Tris, pH 6.8
50% v/v glycerol
10% w/v SDS
25% v/v β-mercaptoethanol
0.25 mg/ml bromphenol blue
Running buffer 25 mM Tris, pH 8.0
192 mM glycerol
1% v/v SDS
Transfer buffer 25mM Tris, pH 8.0
192 mM glycerol
20% v/v methanol
TBS 137 mM NaCl
2.68 mM KCl
24.76 mMTris 
pH 7.8
Blocking buffer 5% w/v non-fat dry milk
0.05% v/v Tween-20 in TBS
Wash buffer 0.05% Tween-20 in TBS
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3. Experimental procedures 
3.1. Molecular biology methods 
3.1.1. Polymerase chain reaction (PCR) 
PCR amplifications for cloning were performed with the proof-reading polymerase Phusion™ 
Flash (Finnzymes – Thermo Scientific). Each reaction contained 1-10 ng of template DNA, 
0.5 µM of both forward and reverse primer, 2× Phusion™ Flash PCR Master Mix (Finnzymes 
– Thermo Scientific) and dH2O to a final volume of 20 µl. The PCR was performed in 
peqSTAR 96 universal thermocyclers (PEQLAB) with the standard programme: 
Cycle step Temp. Time Cycles
Initial denaturation 98 °C 10s 1
Denaturation 98 °C 1s
Annealing x °C  5s 30
Elongation 72 °C 15s/kb
Final extension 72 °C 1min 1
8 °C hold
 
The annealing temperature was set 2-3 °C below the melting temperature (TM) of the primers. 
3.1.2. DNA gel electrophoresis 
Loading dye (Thermo Scientific) was added to samples before separation by gel 
electrophoresis in 1-2%-agarose gels containing 0.5µg/ml ethidium bromide (EtBr) in 1×TAE 
buffer (40 mM Tris Base, 20 mM acetic acid, 1mM EDTA, pH 8.5). The samples were 
separated in an electric field at 10V/cm for 45-60 minutes. The DNA fragments with 
intercalated EtBr were visualised under ultraviolet light (λ=254 nm). GeneRulerTM 1 kb DNA 
ladder (Thermo Scientific) was used to determine the size of DNA fragments. 
For DNA to be used for cloning; bands of interest were cut out of the gel and purified with 
ZymocleanTM Gel DNA Recovery kit (Zymo Research, Irvine, CA, USA), according to the 
manufacturer’s manual. 
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3.1.3. Cloning 
Vectors and inserts were cleaved with restriction enzymes from New England Biolabs (NEB; 
see 2.2.1.). The reactions contained 2-3 µg plasmid or PCR product from an 25-50 µl 
amplification, 5 U restriction enzyme/enzymes (New England Biolabs), the appropriate NEB 
buffers and dH2O to a final volume of 50 µl. The samples were incubated at 37 °C for up to 
3 h. The incubation time was shortened for time-saver enzymes or enzymes with star activity.  
20-80 ng of linearised vector and insert were ligated in reactions containing 1µl T4 DNA 
ligase (New England Biolabs), 10× ligase buffer and dH2O added to 20 µl. Samples were 
incubated for 1 h at room temperature or at 15 °C over night.  
c-FLIPL was cloned into pBluescript (Stratagene – Agilent Technologies, Santa Clara, CA, 
USA) with the enzymes BamHI and XbaI. The c-FLIP isoforms c-FLIPL, c-FLIPS and 
c-FLIPR were inserted into the pIRES2-EGFP vector (Clontech, Mountain View, CA, USA) 
by NheI and SmaI cleavage. HA-c-FLIPL was cleaved with the enzymes NcoI and XbaI 
followed by insertion into the vector pEF/myc/cyto (Life technologies).  
3.1.4. Transformation 
Plasmids were transformed into competent E.coli Top10 bacteria (Life technologies). E.coli 
Top10 were thawed on ice, thereafter 100-200 ng plasmid DNA was added to the bacteria and 
the bacterial suspension was incubated on ice for 20 min. Bacteria were heat shocked in a 
water bath at 42 °C for 30 sec followed by incubation on ice for 2 min. 500 µl LB-medium 
(see 2.2.) was added to the tubes followed by incubation at 37 °C, 800 rpm in a Thermomixer 
comfort (Eppendorf) for 45 min. Bacteria was plated on LB-agar plates containing the 
appropriate antibiotics (100 µg/ml ampicillin or 50 µg/ml kanamycin) and the plates were 
incubated at 37 °C over night. The next day, colonies were picked into 5 ml LB medium for 
mini cultures followed by incubation at 37 °C, 280 rpm, over night. Plasmid DNA was 
isolated by ZyppyTM Plasmid Miniprep kit (Zymo research) according to supplier’s protocol. 
For maxi cultures, 500 µl from a mini culture was inoculated into 200 ml LB-medium. Flasks 
containing the bacterial suspension were incubated at 37 °C, 180 rpm, over night. The next 
day, plasmid DNA was isolated by QIAfilterTM Plasmid Maxi kit (Qiagen, Hilden, Germany) 
by following the manufacturer’s manual. DNA concentrations were determined by measuring 
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the absorbance at 260 nm and 280 nm in a NANODROP 1000 spectrophotometer (PEQLAB). 
1 µg plasmid was analytically cleaved with 1 U restriction enzyme/enzymes (New England 
Biolabs), the appropriate NEB buffer and dH2O to a final volume of 30 µl. The samples were 
incubated at 37 °C for up to 1.5 h. 
3.1.5. Quantitative real-time PCR of patient and tissue samples  
Tissue samples were obtained from patients undergoing cystectomy for urothelial carcinoma 
at the Department of Urology of the Heinrich-Heine-University Duesseldorf between 1995 
and 2004. Twenty-four patients were male and seven were female; average age at surgery was 
69.9 years (range 54–94 years). The samples were selected to comprise all stages and 
included three tumours each staged as pTa or pT1, 5 staged as pT2, 11 staged as pT3 and 7 
staged as pT4. Lymph node metastases were present in seven patients. The lymph node status 
was not determined further for two additional patients with >pT2 cancers. Eleven cancers 
were graded as G2 and 20 as G3. Morphologically normal tissue from 10 patients was used 
for comparison. The use of patient tissues was approved by the Ethics Committee of the 
Medical Faculty of the Heinrich-Heine-University Duesseldorf. Total RNA was isolated from 
5-10×106 cells with the RNeasy kit (Qiagen). Real-time PCR was carried out on an Applied 
Biosystems 7300 Real-Time PCR system using the QuantiTect SYBR Green RT-PCR Kit 
(Qiagen) according to the manufacturer’s instructions. Measurements were run in triplicates 
and normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or TATA-binding 
protein (TBP) values. These assays were performed in cooperation with Dr. Nana Ueffing, 
Prof. Wolfgang Schulz and Christiane Hader, Heinrich-Heine-University, Duesseldorf. 
 
3.2. Cellular and protein biochemical methods 
3.2.1. Transfection and lentiviral infection of cells 
Transient transfections of HEK293T, VMCub1 and SD cells were performed with JetPEI 
(Polyplus transfection, Illkirch, France) according to the manufacturer’s manual. 
VMCub1 and SD cells were stably transduced by lentiviral infections of shRNA targeting 
c-FLIPL, c-FLIPS or both isoforms (c-FLIPL/S). Generation of c-FLIPS shRNA was previously 
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described 147. The c-FLIP MISSION TRC shRNA Target Set was purchased from Sigma-
Aldrich. shRNAs were cloned into the lentiviral vector pLKO.1. Lentiviral vectors were co-
transfected with the envelope vector pMD2.G (Addgene no. 12259) and the gag-pol 
expression plasmid pCMV_dR8.2dvpr (Addgene no. 8455) into HEK293T cells as described 
above. Lentiviruses (LVs) were collected 24 and 48 h after transfection. Crude virus was 
filtered through 0.45 µm PVDF filters (Merck Millipore), concentrated by ultracentrifugation 
at 19 500 × g for 2 h at 12°C and stored at -80°C until further use. SD and VMCub1 cells 
were infected by adding LVs and 5 µg/ml polybrene (Sigma Aldrich) to 2×106 cells. Cells 
were centrifuged at 860 g for 1.5 h at 30°C followed by incubation at 37°C over night. Stably 
transfected clones were selected by limited dilution in medium containing 4 µg/ml puromycin 
(Sigma Aldrich). Specific knockdown of the various c-FLIP isoforms was verified by Western 
blotting. 
Foreign DNA was introduced to Jurkat E6.1 cells by electroporation. For this purpose, 20×106 
cells were washed with PBS containing Ca2+ and Mg2+ (Biochrom). Thereafter cells were 
resuspended in 350µl PBS containing Ca2+ and Mg2+ and transferred to a cuvette 
(Electroporation Cuvette PlusTM, gap size 4 mm, BTX® Harvard Apparatus, Holliston, MA, 
USA). 30 µg DNA was added to the cuvette, cells and DNA were mixed directly followed by 
pulsing in a BioRad Gene Pulser® II with 230 V/ 950 µF, high capacitance. Debris formed 
were removed and cells were transferred back to cell culture flasks with medium. Cells were 
allowed to rest for one day, thereafter two weeks selection with 2 µg/ml puromycin or 
2 mg/ml G418 started. Clones were generated by seeding single cells in 96-well plates. 
3.2.2. Lysis of cells 
5-10×105 cells were lysed in 30-50 µl TPNE lysis buffer for Western blot analyses (see 2.10.) 
with addition of 1 mM PMSF and 1 µg/ml of each leupeptin, aprotinin, chymostatin and 
pepstatin A). 10-50×106 cells to be used for immunoprecipitation were lysed in 0.75-1.5 ml 
DISC lysis buffer (see 2.10. with addition of PMSF, leupeptin, aprotinin, chymostatin and 
pepstatin A as above). Samples were incubated on ice for 15-30 min followed by 
centrifugation at 14,000 rpm, 4 °C for 15 min in an Eppendorf table centrifuge 5417R. 
Supernatants were transferred to 1.5 ml reaction tubes to be used for further experiments. 
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3.2.3. Immunoprecipitation of the DISC complex 
10-50×106 cells per sample (2×106 cells/ml) were either left untreated or stimulated with 
CD95L (scErbB2; sc – single chain, ErbB2 – part of the EGF receptor which enhances 
multimerisation) or 2 µg/ml anti-CD95 (2R2) crosslinked with 10 ng/ml protein A for 30 min. 
The stimulation was stopped by adding 5 volumes of ice-cold PBS, followed by 
centrifugation at 4°C, 1500 rpm, for 5 min. The cells were washed one further time with PBS 
and were thereafter lysed as described above (3.2.2.). 15-20 µl of the whole cell lysates were 
saved for the Western blot as input control. The remaining supernatants were transferred to 
reaction tubes containing the appropriate pre-washed beads for the immunoprecipitation 
(protein A sepharose – Sigma Aldrich, protein G Dynabeads® - Life technologies, Oslo, 
Norway, Flag®M2-agarose – Sigma Aldrich, monoclonal anti-HA-agarose – Sigma Aldrich, 
anti-mouse IgG (whole antibody)-agarose for preclears – Sigma Aldrich). Beads for 
unstimulated samples were pre-incubated with 500 µl CD95L or 2 µg anti-CD95 (2R2) in 500 
µl TBS for 2 h with rotation at 4 °C. Thereafter beads were washed three times with 500 µl 
TBS before whole cell lysates were incubated on beads with rotation at 4 °C for 1.5-3 h. After 
incubation, unbound proteins were removed by washing the beads three times with 500 µl 
DISC lysis buffer. Dry beads were resuspended in 25 µl 1×RSB buffer (see 2.10.) and boiled 
at 95 °C for 5 min. Interacting proteins were identified by SDS-PAGE (see 3.2.4.) followed 
by Western blot analysis (see 3.2.5.) or mass spectrometry analysis (see 3.2.6.). 
3.2.4. SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
Total protein concentration in samples was determined by BCA assay (Pierce Protein 
Research Products – Thermo Scientific) according to manufacturer’s instructions. 5×RSB 
buffer (see 2.10.) was added to 20-40 µg of each sample and boiled at 95 °C for 5 min. 
Proteins were separated in 12% polyacrylamide gels in 1× running buffer  (see 2.10.) with the 
standard PageRulerTM prestained protein ladder (Thermo Scientific) at 80-120 V in a BioRad 
“Tetra Cell”. Proteins were either blotted onto PVDF membranes (see 3.2.5.) or the gels were 
stained with coomassie. For coomassie staining, gels were washed three times 5 min in dH2O, 
thereafter fixed two times 1 h in gel fixation buffer (30% ethanol, 10% acetic acid in dH2O) 
and stained with coomassie (PageBlueTM Protein Staining Solution, Thermo Scientific, 
Rockford, IL, USA) for 1-2 h and washed again three times 5 min in dH2O.  
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3.2.5. Western blotting 
A BioRad “Criterion blotter” was used to transfer proteins separated by SDS-PAGE to a 
PVDF membrane (GE Healthcare, Buckinghamshire, UK) in 1× transfer buffer (see 2.10.) at 
75 V for 1.5 h.  After transfer, membranes were incubated in 5% non-fat dry milk in 
TBS/Tween (blocking buffer; see 2.10.) for 1 h. Membranes were thereafter incubated in 
primary antibodies over night at 4 °C. The next day, unbound antibodies were removed by 
washing membranes three times 10 min in TBS/Tween (see 2.10.) followed by incubation in 
horse-radish peroxidase-coupled secondary antibodies (1:3,000 – 1:20,000) for 1 h at room 
temperature. Subsequently, membranes were washed again as above and developed with one 
of the chemiluminiscent reagents SuperSignal® West Dura Extended Duration Substrate, 
SuperSignal® West Femto Maximum Sensitivity (Pierce Protein Research Products – Thermo 
Scientific) or ECL SelectTM Western Blotting Detection Reagent (GE Healthcare) in the 
Fusion FX-7 camera (Vilber Lourmat). Antibodies were removed from membranes by using 
ReBlot plus mild antibody stripping solution (Merck Millipore) according to manufacturer’s 
protocol. 
3.2.6. Mass spectrometry  
3.2.6.1. Preparation of gel pieces 
Slices from the coomassie gel were cut in small pieces, washed with 30% acetonitrile (ACN) 
in 50 mM ammonium hydrogencarbonate (BIC), reduced with 50 mM dithiothreitol in 50 mM 
BIC for 1 h at 56°C, followed by alcylation with 50 mM iodoacetamide in 50 mM BIC for 1 h 
and incubation in 100% ACN. Finally, gel slices were dried in a SpeedVac centrifuge. 
3.2.6.2. Tryptic digest 
Dried gel pieces were rehydrated in 50 mM BIC containing trypsin at a final ratio of 50:1 
(protein:protease) followed by incubation at 37°C over night. Peptides were washed out three 
times with at least 10 gel volumes of water, 1% trifluoreacetic acid (TFA) and finally with 
0.2% TFA in 30% ACN. 
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3.2.6.3. RP18 CleanUp 
After evaporation of all fluid in the SpeedVac, the peptides were desalted onto ZipTip´s. 
Peptides were resolubilised in 3% ACN containing 0.2% TFA and adsorbed to the RP18 
material. After washing with binding solution, the peptides were eluted with 60% ACN 
containing 0.2% TFA. The peptides were dried in a SpeedVac to remove the organic phase, 
resolubilised in 12 µl 3% ACN containing 0.2% TFA and centrifuged in an ultracentrifuge. 
Peptides were used for LC-MSMS. 
3.2.6.4. LC-MS/MS and data analyses 
LC-MS/MS analyses were performed on a Dionex UltiMate 3000 n-RSLC system connected 
to an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). Peptides were loaded onto 
a C18 pre-column (3 µm, Acclaim, 75 µm x 20 mm, Dionex), washed for 3 min at a flow rate 
of 6 µl/min. Subsequently, peptides were separated on a C18 analytical column (3 µm, Acclaim 
PepMap RSLC, 75 µm x 25 cm, Dionex) at 350 µl/min via a linear 30-min gradient from 
100% buffer A (0.1% formic acid in water) to 25% B (99.9% acetonitrile with 0.1% formic 
acid) followed by a 15 min gradient from 25% buffer to 80% UPLC buffer B. The LC system 
was operated with Chromeleon Software (version 6.8, Dionex), which was embedded in the 
Xcalibur software (version 2.1, Thermo Scientific). The effluent from the column was electro-
sprayed (Pico Tip Emitter Needles, New Objectives, Woburn, MA, USA) into the mass 
spectrometer. The mass spectrometer was controlled by Xcalibur software and operated in the 
data-dependent mode allowing the automatic selection of a maximum of 5 doubly and triply 
charged peptides and their subsequent fragmentation. A dynamic exclusion allowed up to 
3 repeats.  Peptide fragmentation was carried out using LTQ settings (Min signal 2000, 
Isolation width 4, Normalised collision energy 35, Default Charge State 4 and Activation time 
10 ms).  MS/MS raw data files were processed via Mascot Daemon-aided (version 2.8, Matrix 
Science) searches against UniProtKB/Swiss-Prot protein database (release 2011_03, with 
525,997 entries on a Mascot server (V. 2.3.02, Matrix Science, Boston, MA, USA) or using 
the Proteome Discoverer program Version 1.3 (Thermo Scientific). The following search 
parameters were used: enzyme - trypsin; maximum missed cleavages - 1; fixed modification - 
Carbamidomethylation (C); variable modifications - oxidation (M), phosphorylation of S, T 
and Y, respectively; peptide tolerance, 5 ppm; MS/MS tolerance, 0.4 Da. The mass 
spectrometry analyses were performed by Dr. Josef Wissing (Cellular Proteome Research 
group, Helmholtz Centre for Infection Research, Brunswick, Germany) 
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3.2.7. Flow cytometry analyses  
For flow cytometry analysis, 1×106 cells were washed in 1 ml PBS at 4 °C, 1500 rpm, 5 min. 
Cells were resuspended in 100 µl PBS and stained with LIVE/DEAD® (see 2.7.1.; Life 
technologies) for 30 min, 4 °C in the dark, if required. Thereafter cells were washed in 1 ml 
PBS as above.  
Surface markers were stained in 100 µl FACS buffer (see 2.10.). Cells were incubated with 
appropriate dilutions of fluorochrome-conjugated or unconjugated antibodies (see 2.7.2. and 
2.7.3.) at 4 °C for 20 min in the dark. Unbound antibodies were washed away with 1 ml 
FACS buffer. In the case of unconjugated antibodies, cells were incubated with a secondary 
PE-conjugated antibody (0.75 µg per test) for 20 min as above followed by another wash step. 
For intracellular staining of active caspase-3, cells were fixed and permeabilised in 100 µl BD 
Cytofix/CytopermTM fixation and permeabilisation solution for 20 min at 4 °C. Thereafter 
cells were washed two times with 1 ml 1× BD Perm/WashTM buffer. Staining of active 
caspase-3 was done in 50 µl BD Wash/PermTM buffer with incubation at 4 °C for 30 min 
followed by a further washing step with 1× BD Perm/WashTM buffer as above. 
Apoptosis was assayed by AnnexinV and 7-amino-actinomycin D (7AAD) staining. For this 
staining, surface marker staining was first performed as above. Thereafter cells were 
resuspended in 100 µl 1× annexin binding buffer (see 2.10.) containing 3 µl AnnexinV and 
0.2 µg 7AAD. Samples were incubated at room temperature for 15 min and finally, 150 µl 
1× annexin binding buffer was added.  
Another method used to assay apoptosis was quantification of the sub-G1 DNA content. For 
this assay, PBS washed cells were incubated in 250 µl Nicoletti buffer (see 2.10.) for at least 
1 h at 4 °C in the dark, before flow cytometry analysis. 
3.2.8. Cell isolation by flow cytometry   
Primary cells were stained with surface markers as in 2.2.7. and were sorted in the FACS Aria 
II  (BD Biosciences) or MoFlo (Beckman and Coulter). Isolated cells were collected in tubes 
containing 1 ml primary cell medium (see 3.3.1.). Sorting was performed in cooperation with 
Dr. Lothar Groebe at the flow cytometry facility, Helmholtz Centre for Infection Research, 
Brunswick, Germany. 
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3.3. Mouse and primary murine cell methods 
3.3.1. Isolation of organs and cell preparation 
Lymphoid organs (peripheral lymph nodes (pLN), mesenteric lymph nodes (mLN), spleen 
and thymus) were isolated from mice sacrificed by CO2. Organs were homogenised through a 
70 µm nylon mesh and washed with PBS. Erythrocytes were removed by 2 min incubation in 
ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH adjusted to 7.3 with 
NaOH) at room temperature followed by a further washing step.  
Primary murine cells were cultured in RPMI 1640 supplemented with 10% FCS, 50 µg/ml of 
penicillin and streptomycin, 1% non-essential amino acids, 2 mM L-glutamine and 1 mM 
sodium pyruvate. 
3.3.2. In vitro activation of T and B cells 
T cells were activated by seeding 1×106 splenocytes or lymph node cells in 24-well plates 
followed by stimulation with 2 µg/ml concanvalin A (Con A; Sigma Aldrich) or 2 µg/ml anti-
CD3 (145-2C11, BioLegend) and 2 µg/ml anti-CD28 (37.51, BioLegend), both plate-bound, 
for up four days.  
CD19+ cells were sorted from spleen, peripheral and mesenteric lymph nodes of 8-12 weeks 
old mice. After sorting, cells were activated by stimulating 2×106 cells per well in 24-well 
plates with 10 µg/ml LPS for 48 h. 
3.3.3. Apoptosis assays 
For assaying thymocyte apoptosis, 1×106 thymocytes isolated from 6-8 weeks old mice were 
seeded in 24-well plates and either left untreated or stimulated for up to 16 h with 50 ng/ml 
CD95L (scErbB2), 1 µg/ml anti-CD95 (Jo-2; BD Biosciences) crosslinked with 10 ng/ml 
protein A (Sigma Aldrich) or 1 µM dexamethasone (Sigma-Aldrich). Viable cells were 
quantified by flow cytometry by staining with AnnexinV and 7AAD as described in 3.2.7.  
CD4+ and CD8+ cells were sorted from spleen, pLN and mLN of 8-12 weeks old mice. 5×105 
cells were seeded per well in 96-well plates and stimulated with 50 ng/ml CD95L or 1 µM 
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dexamethasone for 16 h. Apoptosis was assayed by staining with AnnexinV and 7AAD as 
above. 
Sorted and activated B cells (see 3.3.2.) were seeded with 4×105 cells per well in 96-well 
plates and stimulated for 16 h with 100 ng/ml CD95L or 1 µM dexamethasone. Thereafter, 
cells were stained for AnnexinV and 7AAD as described above. The specific apoptosis was 
calculated as ((experimental apoptosis (%) – spontaneous apoptosis (%)) / (100% - 
spontaneous apoptosis)) × 100. 
3.3.4. Activation induced cell death 
Peripheral lymph node cells were isolated from 6-8 weeks old mice. 1×106 cells were seeded 
per well in 24-well plates coated with 10 µg/ml anti-CD3 (145-2C11) and 2 µg/ml anti-CD28 
(E18). 20 ng/ml IL-2 was added to the media. The cells were taken off the anti-CD3, anti-
CD28 stimuli on day 2 and expanded for 3 further days in the presence of IL-2. On day 5, T 
cell blasts were tested for activation induced cell death (AICD) by 6 h restimulation with 10 
µg/ml plate-bound anti-CD3. The cells were thereafter stained for AnnexinV and 7AAD as 
described in 3.2.7. The specific apoptosis was calculated as described in 3.3.3. 
3.3.5. Experimental autoimmune encephalomyelitis (EAE)  
EAE was induced in 10-12 weeks old WT and vavFLIPR mice by injecting 200 µg MOG(35-
55)-peptide (MEVGWYRSPFSRVVHLYRNGK) together with 4 mg/ml mycobacteria in 
CFA subcutaneously at four sites. 200 ng pertussis toxin was injected intraperitoneally to 
open the blood-brain-barrier. The pertussis toxin injection was repeated two days later. Mice 
were monitored daily for clinical signs of EAE from day 3 to day 40 according to table 1. 
Mice with a score higher than 3 were sacrificed. The EAE was performed in cooperation with 
Michaela Annemann (Systems-oriented Immunology and Inflammation Research, Helmholtz 
Centre for Infection Research, Brunswick, Germany/ Institute of Molecular and Clinical 
Immunology, Otto-von-Guericke University, Magdeburg).  
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Table 1. EAE scoring system 
Score Symptoms
     0 None
     0.5 Partial limp tail
     1 Limp tail
     2 Delayed  rotation from dorsal position
     2.5 Hindleg weakness
     3 Complete hindleg paralysis 
     3.5 Starting foreleg weakness 
     4 Paralysis of one foreleg 
     5 Moribund, death 
 
 
3.3.6. Histology  
Kidneys and livers were isolated from one year old WT and vavFLIPR mice. Organs were 
fixed in 4% paraformaldehyde and embedded in paraffin for histological analysis. 1.5-2 µm 
sections from liver and kidney were stained with hematoxylin and eosin (H&E). Moreover, 
kidney sections were stained with periodic acid schiff (PAS) staining. Kidney sections were 
analysed for thickening of the Bowman’s capsule and protein casts in glomeruli and distal 
tubuli. The liver sections were analysed for the amount of microgranuloma and liver 
associated lymphoid tissue. Scoring was performed in a blinded manner by Dr. Marina Pils 
(Histology facility at Helmholtz Centre for Infection Research, Brunswick, Germany) as 
follows: 0 – no alteration, 1 – low grade (slightly visible), 2 – moderate (clearly visible), 3 – 
severe. Scores were added to a total score for each organ. 
3.3.7. Analysis of anti-nuclear antibodies (ANA assay) 
Anti-nuclear antibodies in sera from 1 year old WT and vavFLIPR mice were analysed semi-
quantitatively by incubating HEp-2 cells seeded on microscope slides with sera diluted 1:80 – 
1:1280 for 30 min at room temperature. Slides were washed two times 5 min in PBS followed 
by incubation with FITC-conjugated donkey anti-mouse IgG (Dianova, Hamburg, Germany) 
for 30 min in the dark. Thereafter slides were washed two times 5 min PBS, transferred to 
cover slips and sealed. Slides were analysed by fluorescence microscopy where a 
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homogenous pattern was considered as positive for ANAs. The ANA assays were performed 
in cooperation with Prof. Dr. Dirk Reinhold (Institute of Molecular and Clinical Immunology, 
Otto-von-Guericke University, Magdeburg), who prepared and analysed the slides. 
 
3.4. Statistical analysis 
The software Graph Pad Prism from Graph-Pad-Software Inc (La Jolla, CA, USA) was used 
for all statistical analyses. One- or two-tailed non-parametric Mann Whitney U tests were 
performed to calculate statistical significances. Error bars were presented as standard 
deviation (s.d.) or standard error of the mean (s.e.m.). 
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4. Results 
4.1. The role of c-FLIP splice variants in urothelial tumours 
4.1.1. c-FLIPL expression is decreased in urothelial carcinoma 
c-FLIP expression has been reported to be upregulated in several types of cancer, i.e. 
Hodgkin’s lymphoma 189, 190 and melanoma 141, 191. Cancer of the urinary bladder is one of the 
most common cancer types in men in Europe and the United States. For this reason, 
expression of c-FLIPL and c-FLIPS mRNA in urothelial carcinoma samples were analysed. 
Surprisingly, c-FLIPL mRNA levels were moderately but significantly decreased in tumour 
samples compared to normal urothelial tissue (Figure 11A). Similarly, the expression of 
c-FLIPL as quantified by real-time PCR was lower in urothelial carcinoma cell lines than in 
cultured normal urothelial cells (NUC; Figure 11B). c-FLIPS was not differentially expressed 
between either tissues or cell lines (Figure 11A, B).  
 
 
Figure 11. (A) Quantification of c-FLIPL and c-FLIPS mRNA levels in normal urothelial tissues (normal; 
n=10) and urothelial carcinoma samples (tumour; n=28) by quantitative RT-PCR. Values were normalised 
to GAPDH expression. Horizontal lines represent the mean; error bars display the standard deviation (s.d.). 
(B) Quantification of c-FLIPL and c-FLIPS mRNA levels in normal urothelial cells (NUCs; n=7) and 
urothelial cell lines (cell line; n=19) by quantitative RT-PCR. Values were normalised to TBP expression 
levels. Horizontal lines display the mean ± s.d. Statistical analyses were performed by non-parametric two-
tailed Mann Whitney U tests. 
 
The urothelial carcinoma cell lines VMCub1 and SD were chosen as cell models to determine 
whether even lower levels of c-FLIP can mediate resistance towards death receptor-mediated 
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apoptosis and to investigate the role of c-FLIP splice variants in urothelial carcinoma. The cell 
lines were selected based on their death receptor and c-FLIP expression profile. 
4.1.2. Cycloheximide sensitises urothelial carcinoma cell lines towards CD95L- and 
TRAIL-induced apoptosis 
To investigate whether the extrinsic pathway can be triggered in VMCub1 and SD, the death 
receptor expression of these cell lines was analysed by surface staining and flow cytometry 
analysis of the death receptors CD95, TRAIL-R1, TRAIL-R2 and TNF-R1. VMCub1 cells 
had a moderate to high expression of CD95, TRAIL-R2 and TNF-R1, whereas SD cells had a 
moderate to high expression of all four death receptors (Figure 12). 
 
 
Figure 12. Death receptor expression of urothelial carcinoma cell lines. VMCub1 and SD cell surface 
expression of the death receptors CD95, TRAIL-R1, TRAIL-R2 and TNF-R1 analysed by flow cytometry 
(grey). Unstained cells are shown in white. 
 
To assess CD95L- and TRAIL-induced apoptosis of VMCub1 and SD, cells were stimulated 
with the ligands for 16 h and 24 h, respectively, before measurement of DNA fragmentation. 
Both urothelial carcinoma cell lines showed low sensitivity towards CD95L-induced (Figure 
13A) as well as TRAIL-induced (Figure 13B) apoptosis. However, VMCub1 and SD cells 
were strongly sensitised towards apoptosis by addition of the protein translation inhibitor 
cycloheximide (CHX; Figure 13A, B). 
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Figure 13. Urothelial carcinoma cell lines VMCub1 and SD are sensitised to apoptosis by cycloheximide 
(CHX). For analysis of apoptosis sensitivity, urothelial carcinoma cells were left untreated or stimulated for 
16 h or 24 h, respectively, with the indicated concentrations of CD95L (A) or TRAIL (B) in the presence or 
absence of 10 µg/ml CHX. The amount of apoptotic cells was determined by quantification of sub-G1 
DNA content by flow cytometry. Data are displayed as the mean of at least three measurements (± s.d.). 
 
An additional method to measure apoptosis is analysis of caspase processing, as the initiator 
caspase-8 and the effector caspase-3 are activated by proteolytic cleavage upon death receptor 
stimulation. For this purpose, VMCub1 and SD cells were stimulated either with CD95L for 
up to 8 h (Figure 14A) or with TRAIL for up to 24 h (Figure 14B) in the absence or presence 
of cycloheximide, followed by Western blotting to examine caspase cleavage as an early 
event during apoptosis. There was only minimal cleavage of caspase-8 and caspase-3 after 
stimulation with CD95L or TRAIL alone, whereas the presence of cycloheximide caused 
substantial processing of both caspases. Taken together, the results indicate that short-lived 
proteins play an important role in protecting the urothelial carcinoma cells against apoptosis. 
In particular, at least one short-lived protein protects against apoptosis at a step prior to 
caspase-8 activation, for which c-FLIP is the most likely candidate 175, 241. It was previously 
shown in the working group that both c-FLIPL and c-FLIPS have a short half-life in VMCub1 
and SD cells 237, giving further evidence that c-FLIP proteins are likely candidates for causing 
the reduced susceptibility to apoptosis in the urothelial carcinoma cell lines. 
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Figure 14. Analysis of CD95L- and TRAIL-induced apoptosis in urothelial carcinoma cells. VMCub1 and 
SD cells were left untreated or stimulated for the indicated times with 0.4 ng/ml CD95L (A) or 25 ng/ml 
TRAIL (B) in the presence or absence of 10 µg/ml CHX. Cleavage of caspase-8 and caspase-3 was 
analysed by Western blotting with β-actin as the loading control. 
 
4.1.3. c-FLIP overexpression protects urothelial carcinoma cells against apoptosis 
It is known that all three human c-FLIP splice variants can inhibit death receptor-mediated 
apoptosis 118, 140, 149. For this reason, it was investigated whether overexpression of any c-FLIP 
isoform could protect VMCub1 and SD cells against apoptosis. The three c-FLIP splice 
variants c-FLIPL, c-FLIPS and c-FLIPR were cloned into a vector, which allows tracking of 
transfected cells by internal ribosomal entry site (IRES)-driven GFP expression. The 
generated constructs were first transiently transfected into HEK293T cells to verify that the 
respective c-FLIP variants were expressed at the protein level together with GFP (Figure 
15A). Thereafter, VMCub1 and SD cells were transiently transfected with either the empty 
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vector or one of the c-FLIP constructs. The cells were stimulated with CD95L and the 
intracellular levels of active caspase-3 were examined by flow cytometry. Indeed, both 
VMCub1 (Figure 15B, C) and SD cells (Figure 15D, E) were protected by overexpression of 
any c-FLIP variant against CD95L-mediated apoptosis. The protective effect of c-FLIP 
overexpression was also confirmed by staining of transfected and stimulated cells using 
tetramethylrhodamine ethyl ester (TMRE, Figure 16).  
 
Figure 15. Overexpression of c-FLIP proteins protect urothelial carcinoma cells against CD95-mediated 
apoptosis. (A) Original pEF-vectors and the generated pIRES2EGFP-c-FLIP constructs were transiently 
transfected into HEK293T cells. The c-FLIP and GFP protein expression was analysed by Western blotting 
with tubulin as the loading control. pIRES2EGFP-c-FLIP constructs were transiently overexpressed in 
VMCub1 cells (B, C) and SD cells (D, E). The urothelial carcinoma cells were left untreated or stimulated 
with 1 ng/ml CD95L for 4 h. Sensitivity to apoptosis in transfected cells was analysed by flow cytometry. 
Intracellular staining of active caspase-3 was used as a marker for apoptotic cells and the transfected cells 
were identified by GFP expression. (B, D) Histograms are representative for three independent experiments 
with percentages shown for stimulated samples. (C, E) Data are shown as the percentages within the GFP-
positive population with the mean of three independent experiments (± s.d.). 
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Figure 16. CD95-mediated apoptosis is inhibited by overexpression of c-FLIP proteins. VMCub1 (A) and 
SD cells (B) were transiently transfected with pIRES2EGFP-c-FLIP constructs followed by CD95L-
stimulation as described in figure 5. Cells were stained with TMRE and analysed by flow cytometry. 
Apoptotic cells within the GFP-positive population were identified as TMRE negative. Data are 
represented as the mean of two independent experiments (± s.d.) except stimulated empty vector control of 
SD cells where one measurement is shown.  
4.1.4. Knock-down of c-FLIP sensitises urothelial carcinoma cells for CD95L-induced 
apoptosis 
As high expression of all c-FLIP isoforms is reported to block death receptor-mediated 
apoptosis 118, 140, 242, a loss-of-function approach was followed to determine specific functions 
of the different c-FLIP splice variants. For this, previously generated VMCub1 and SD cells 
stably transduced with lentiviral shRNA constructs targeting c-FLIPL, c-FLIPS or both 
c-FLIPL/S isoforms were used (Figure 17). The knock-down of c-FLIPL was less efficient than 
the c-FLIPS and c-FLIPL/S knock-downs. 
 
Figure 17. Stably transduced VMCub1 or SD cells lentivirally infected with a control shRNA (C) or 
shRNAs targeting c-FLIPL (L), c-FLIPS (S) or both c-FLIPL and c-FLIPS (L/S). Knock-down of the c-FLIP 
isoforms was confirmed by Western blotting. β-actin served as the loading control. 
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As assessed by measurement of DNA fragmentation, stimulation of VMCub1 and SD knock-
down cells with increasing concentrations of CD95L led to elevated levels of apoptosis in the 
c-FLIPL/S double knock-down cells (Figure 18A, B). The effect was most prominent for the 
SD cells expressing shRNAs targeting both c-FLIPL and c-FLIPS, where the extent of 
apoptosis was comparable to those of wild type SD cells treated with cycloheximide (Figure 
13A). This finding strongly supports the argument that c-FLIP is a prominent short-lived anti-
apoptotic protein in these cells. Moreover, SD cells with knock-down of c-FLIPL alone were 
highly susceptible towards CD95L-induced apoptosis, whereas SD cells with knock-down of 
c-FLIPS alone remained resistant (Figure 18B). VMCub1 cells with single knock-down of 
c-FLIPL or c-FLIPS showed a mild, but statistically significant increase in CD95L-mediated 
apoptosis (Figure 18A).  
 
 
Figure 18. Knock-down of c-FLIPL/S sensitises VMCub1 and SD cells towards CD95L-induced apoptosis. 
For analysis of apoptosis sensitivity, VMCub1(A) and SD cells (B) stably transduced with the indicated 
shRNAs against c-FLIPL, c-FLIPS or both isoforms (c-FLIPL/S) were left untreated or stimulated for 16 h 
with the indicated concentrations of CD95L. The amount of apoptotic cells was quantified by DNA 
fragmentation analysed by flow cytometry. Data are shown as the mean of four measurements (± s.d.). 
Statistical analyses was performed by two-tailed Mann Whitney U tests, asterisks (*) indicate p<0.05 with 
respect to scramble controls.  
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The effects of c-FLIPL or c-FLIPS knock-down on DNA fragmentation were paralleled by 
effects on caspase processing. The most extensive cleavage of caspase-8 and caspase-3 was 
observed in VMCub1 and SD c-FLIPL/S double knock-down cells as well as SD c-FLIPL 
single knock-down cells, where the proform of caspase-8 was extensively processed to the 
cleavage products p41/43 and p18 of caspase-8 as well as p17/20 of caspase-3 (Figure 
19A, B). In contrast, both caspase-8 and caspase-3 remained uncleaved in VMCub1 and SD 
cells transduced with scramble shRNA. Thus, c-FLIP proteins protect the urothelial 
carcinoma cells against CD95L-induced apoptosis. Furthermore, the long c-FLIP isoform 
appears to be more important. 
 
 
Figure 19. Analysis of caspase-8 and caspase-3 processing upon CD95L-stimulation. VMCub1 (A) and SD 
cells (B) with knock-down of c-FLIPL/S, c-FLIPL or c-FLIPS were left untreated or stimulated with 
0.4 ng/ml and 0.8 ng/ml CD95L, respectively, for the times indicated. Cleavage of caspase-8 and -3 was 
analysed by Western blotting. Expression of β-actin is presented as the loading control. 
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4.1.5. Urothelial carcinoma cells are sensitised for TRAIL-induced apoptosis by knock-
down of c-FLIP 
Next, the effect of isoform-specific c-FLIP knock-down on TRAIL-mediated apoptosis in 
VMCub1 and SD cells was investigated. Susceptibility to TRAIL-induced apoptosis was 
assayed by measurement of DNA fragmentation. Comparable to the CD95L-induced 
apoptosis assays, the VMCub1 and SD c-FLIPL/S double knock-down cells as well as the SD 
c-FLIPL single knock-down cells showed elevated levels of apoptosis upon TRAIL 
stimulation (Figure 20A, B). 
 
 
Figure 20. Effect of c-FLIP isoform knockdown on the susceptibility of urothelial carcinoma cells to 
TRAIL-induced apoptosis. VMCub1 (A) and SD cells (B) with knockdown of c-FLIPL, c-FLIPS or both 
isoforms (c-FLIPL/S) were left untreated or stimulated with 25 ng/ml TRAIL for 24 h. The amount of 
apoptotic cells was quantified by measuring the sub-G1 DNA content by flow cytometry. Data are shown 
as the mean of at least three measurements (± s.d.). 
 
To assess activation of caspase-8 and caspase-3, cells were stimulated with TRAIL for up to 
24 h. The cleavage products of caspase-8 and caspase-3 were readily detected in the VMCub1 
c-FLIPL/S double knock-down cells upon TRAIL-stimulation, indicating activation of both 
caspases (Figure 21A). Small amounts of both processed caspases could also be detected in 
VMCub1 cells expressing shRNAs targeting c-FLIPL or c-FLIPS alone, suggesting that the 
c-FLIP isoforms are not complementary. In SD cells, the cleavage products p18/41/43 of 
caspase-8 and p17/20 of caspase-3 were clearly detected in c-FLIPL/S double knock-down 
cells as well as in c-FLIPL single knock-down cells. Moreover, the proform of both caspase-8 
and caspase-3 was extensively degraded in SD cells expressing shRNAs targeting both 
c-FLIPL and c-FLIPS at later time points (Figure 21B). In contrast, both caspases remained 
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uncleaved in VMCub1 and SD cells stably transduced with scramble shRNAs suggesting that 
c-FLIP proteins confer broad resistance to death receptor activation in urothelial carcinoma.  
 
 
Figure 21. Analysis of caspase-8 and caspase-3 processing upon TRAIL-stimulation. For analysis of 
caspase-8 and caspase-3 cleavage, VMCub1 (A) and SD cells (B) stably transduced with the indicated 
shRNAs directed against c-FLIPL, c-FLIPS or both (c-FLIPL/S) were left untreated or stimulated with 
25 ng/ml TRAIL for times as indicated. Lysates were analysed by Western blotting with β-actin as the 
loading control. 
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4.2. Identification of novel CD95 DISC-interacting proteins 
4.2.1. Characterisation of Jurkat E6.1 clones overexpressing c-FLIPL 
The Jurkat E6.1 cell line was chosen for mass spectrometry (MS) analysis, since the MS 
analyses require a high amount of protein. Moreover, Jurkat cells are well characterised and 
different knock-out cell lines are available 243-245.  
 
 
Figure 22. Protein expression in Jurkat E6.1 c-FLIPL overexpressing clones. The expression of c-FLIPL, 
caspase-8 and FADD in Jurkat E6.1 clones overexpressing Flag-c-FLIPL (A) or HA-c-FLIPL (B) was 
analysed via Western blotting. Expression of β-actin ensured equal loading. Parental Jurkat E6.1 cells were 
used as control (Ctr) in (A). (C) Lysates of parental Jurkat E6.1 cells (Ctr), empty vector control (EV) and 
HA-c-FLIPL cl. 20 and cl. 32 as well as Flag-c-FLIPL cl. 16 were immunoblotted to analyse the expression 
of c-FLIPL, Bcl-2, caspase-3, -8 ,-9, FADD, RIP1 and XIAP. β-actin served as the loading control. Left-
over of c-FLIPL is marked by an asterisk (*).  
 
HA- or Flag-tagged c-FLIPL was stably overexpressed in Jurkat E6.1 cells and single clones 
were generated by limited dilution. The protein expression of c-FLIPL, caspase-8 and FADD 
was analysed by Western blotting to identify clones with high expression of c-FLIPL (Figure 
22A, B). HA-tagged c-FLIPL clones 20 and 32 as well as Flag-tagged c-FLIPL clone 16 were 
chosen for further experiments. Moreover, a clone stably transfected with the empty vector 
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was chosen as control. In these clones, the expression of further apoptosis proteins (Bcl-2, 
caspase-3, -8, -9, FADD, RIP1 and XIAP) was analysed. The expression levels remained 
constant; the only exception was caspase-8 where slightly less protein could be detected in 
c-FLIPL overexpressing clones (Figure 22C). Furthermore, overexpression of c-FLIPL did not 
affect the death receptor expression. High expression of CD95 was observed in parental 
Jurkat cells and all clones. The expression of TRAIL-R2 and TNF-R1 was low to moderate in 
all cell lines (Figure 23).  
 
 
Figure 23. Death receptor expression of Jurkat E6.1 c-FLIPL overexpressing clones. Expression of the 
death receptors CD95, TRAIL-R2 and TNF-R1 was analysed by flow cytometry. Parental Jurkat cells and 
Jurkat Flag-c-FLIPL cl. 16 are shown in (A) with cells stained for death receptors in grey and unstained 
cells in white. The death receptor expression of parental Jurkat cells, empty vector control and HA-c-FLIPL 
clones 20 and 32 are shown in (B). Cells stained for death receptors are shown in grey; white histograms 
represent Jurkat cells stained with secondary antibody alone. 
 
c-FLIP proteins are well-known inhibitors of apoptosis 118, 140, 141, 149. Therefore, the sensitivity 
towards CD95-induced apoptosis was analysed in Jurkat clones overexpressing c-FLIPL by 
measurement of sub-G1 DNA content (Figure 24A, C). The clones were stimulated with anti-
CD95 for up to eight hours, followed by flow cytometry analysis. A large fraction of empty 
vector control cells and parental Jurkat E6.1 cells were dying already after four hours 
stimulation, whereas Jurkat cells overexpressing c-FLIPL were protected against CD95-
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induced apoptosis. Additionally, HA-c-FLIPL clones 20 and 32 were stimulated with the 
indicated concentrations of anti-CD95 over night (Figure 24B). 0.1 µg/ml anti-CD95 was 
enough to induce apoptosis in empty vector control cells, whereas only background apoptosis 
could be identified in c-FLIPL overexpressing clones. Moreover, lower levels of DNA 
fragmentation were observed upon stimulation with 1 µg/ml anti-CD95 in c-FLIPL over-
expressing clones in comparison to the empty vector control. Finally, the apoptosis sensitivity 
was compared between the Flag-c-FLIPL cl. 16 and HA-c-FLIPL cl. 32. The c-FLIPL 
overexpressing clones were similarly protected against CD95L-induced apoptosis (Figure 
24D).   
 
 
Figure 24. CD95-induced apoptosis of Jurkat clones overexpressing c-FLIPL. (A, C) For assaying 
apoptosis, Jurkat empty vector control, HA-c-FLIPL clones 20 and 32 (A) as well as Flag-c-FLIPL cl. 16 
(C) were stimulated with 1µg/ml anti-CD95 (2R2) for the indicated times. (B, D) The Jurkat clones HA-
c-FLIPL 20, 32 and Flag-c-FLIPL cl. 16 were stimulated with the indicated concentrations of anti-CD95 (B) 
or CD95L (D) for 16 h. The amount of apoptotic cells was quantified as DNA fragmentation analysed by 
flow cytometry. Data are shown as the mean (± s.e.m.) of triplicates. 
 
Further, the apoptosis sensitivity was assayed by analysing the early apoptosis events of 
caspase-8 and caspase-3 processing upon CD95L-stimulation. For this, Jurkat empty vector 
control cells as well as HA-c-FLIPL overexpressing clones 20 and 32 were stimulated with 
CD95L for up to eight hours. The cleavage of caspase-8 into the p41/43 and p18 fragments as 
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well as the processing of caspase-3 into p17/20 was identified in the empty vector control 
cells, in contrast to c-FLIPL overexpressing clones where no caspase-processing could be 
detected (Figure 25A). Taken together, the clones with c-FLIPL overexpression are indeed 
protected against CD95-induced apoptosis. 
 
 
Figure 25. Apoptosis sensitivity and NF-κB activation in Jurkat HA-c-FLIPL clones. (A) Jurkat empty 
vector and HA-c-FLIPL overexpressing clones (5×105 cells per sample) were stimulated with 10 ng/ml 
CD95L for up to 8 h. c-FLIPL expression and cleavage of caspase-8 and caspase-3 was analysed by 
Western blotting. β-actin was used as the loading control. (B, C) To assay NF-κB activation of Jurkat 
empty vector and HA-c-FLIPL clones 20 and 32, 5×105 cells per sample were stimulated with 20 ng/ml 
PMA and 1µM ionomycin for the indicated times. Proteins were blotted onto PVDF membranes and 
probed for phospho-IκBα (p-IκBα), IκBα and c-FLIP with tubulin as the loading control. 
 
c-FLIP protein has been reported as an activator of NF-κB 204, 206, 207. The NF-κB activation 
was examined in HA-c-FLIPL clones by analysing the expression of phospho-IκBα and total 
IκBα upon PMA/ionomycin stimulation (Figure 25B, C). Indeed, the phosphorylation of 
IκBα was prolonged and enhanced in cells with c-FLIPL overexpression. Moreover, total 
IκBα levels elevated upon stimulation in c-FLIPL overexpressing clones compared to empty 
vector control cells. The effect was more pronounced in HA-c-FLIPL cl. 32 (Figure 25C), 
which has higher c-FLIPL expression than HA-c-FLIPL cl. 20 (Figure 25B).  
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4.2.2.  Immunoprecipitation of the DISC complex in c-FLIPL overexpressing clones  
The death-inducing signalling complex (DISC) was immunoprecipitated upon CD95L-
stimulation in empty vector control cells as well as HA-c-FLIPL clones 20 and 32. The 
complex consisted of the CD95 receptor, the adaptor protein FADD as well as the DED-
containing proteins c-FLIP and caspase-8 in all cell lines. Caspase-8 becomes enzymatically 
activated at the DISC, which was identified by caspase-8- and c-FLIPL-cleavage in immuno-
precipitated samples. Caspase-8 was fully processed into the p41/43 products in all cell lines 
as well as p18 for empty vector control cells, whereas some full-length c-FLIPL still could be 
detected in c-FLIPL overexpressing cells. c-FLIP proteins or heterodimers of c-FLIP and 
caspase-8 have higher affinity for the DISC complex 118. Therefore, it was not unexpected that 
less caspase-8 was identified in the DISCs of c-FLIPL overexpressing cells compared to 
empty vector control cells.  
 
 
Figure 26. Immunoprecipitation of the DISC complex in Jurkat clones overexpressing HA-c-FLIPL. Jurkat 
clones overexpressing HA-c-FLIPL cl. 20 and 32 as well as empty vector control cells (10×106 cells per 
sample) were stimulated with Flag-tagged CD95L for 30 min or left untreated, followed by lysis of the 
cells and immunoprecipitation of the DISC-complex on Flag-beads. Western blotting was performed to 
analyse the DISC complex, with antibodies directed against CD95, FADD, c-FLIP, TRAF2, RIP1 and 
caspase-8 proteins.  
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A small amount of RIP1 was identified in all DISCs with slightly more RIP1 in the DISC of 
cl. 32, which has the highest c-FLIPL expression. TRAF2 was recruited to the DISC in a 
c-FLIPL-dependent manner (Figure 26). 
 
Next, c-FLIPL was immunoprecipitated with interacting proteins. The Jurkat cells were either 
left untreated or stimulated with CD95L or anti-CD95, followed by immunoprecipitation on 
anti-HA or anti-Flag beads. The DISC-components caspase-8, FADD and the CD95 receptor 
was immunoprecipitated upon stimulation in both HA-c-FLIPL and Flag-c-FLIPL clones 
(Figure 27A, B). Additionally, TRAF2 was recruited to Flag-c-FLIPL upon stimulation. 
c-FLIPL-interaction and cleavage of RIP1 could also be observed upon stimulation in Flag-
c-FLIPL overexpressing cells (Figure 27B). 
 
 
Figure 27. Immunoprecipitation of c-FLIPL upon CD95L- or anti-CD95-stimulation. Jurkat clones 
overexpressing HA-tagged (A) and Flag-tagged (B) c-FLIPL as well as empty vector controls were either 
left untreated or stimulated with (A) CD95L (10×106 cells per sample) or (B) 2 µg/ml anti-CD95 (2R2) 
crosslinked with 10 ng/ml Protein A (30×106 cells per sample), followed by immunoprecipitation of 
c-FLIPL on HA- or Flag-agarose beads. Western blot analyses of c-FLIP, caspase-8, FADD, CD95, TRAF2 
and RIP1 were performed to identify interacting proteins. 
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4.2.3. Mass spectrometry analysis of proteins interacting at the DISC 
Mass spectrometry can identify large numbers of proteins from one single immuno-
precipitation and abundant proteins can cause difficulties in identifying low-expressed 
proteins. Therefore, it is of importance that the beads used give rise to as little unspecific 
binding as possible to increase the chance of identifying specific interactions. For this reason 
HA-c-FLIPL cl. 32 cells were left untreated or stimulated with CD95L, subsequently lysed 
and divided up onto HA- and Flag-beads. The coomassie-staining of the 
immunoprecipitations clearly showed that the Flag-beads give rise to less unspecific binding 
(Figure 28). Consequently, these beads were used for the immunoprecipitations for the mass 
spectrometry analyses. 
 
Figure 28. Comparison between HA IP (c-FLIPL IP) and Flag IP (DISC IP). 100×106 Jurkat HA-c-FLIPL 
cl.32 cells were either left untreated or stimulated with Flag-tagged CD95L for 30 min. Cells were 
thereafter lysed and divided onto HA- and Flag-agarose beads for immunoprecipitation. 
Immunoprecipitated samples were run on an SDS-gel followed by coomassie-staining. 
 
Immunoprecipitations for mass spectrometry analyses were performed with 1.5×108 cells for 
each sample. Samples were incubated two times on control IgG beads before the actual Flag-
immunoprecipitation to reduce unspecific binding. The Flag-immunoprecipitation was 
controlled by Western blotting (Figure 29A) before samples were run on an SDS-gel followed 
by coomassie-staining. The lanes on the coomassie-gels were cut in 17 slices and these slices 
were analysed by mass spectrometry (Figure 29B).  
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Figure 29. DISC immunoprecipitation for mass spectrometry analysis. DISC formation was induced by 
stimulating 1.5×108 Jurkat HA-c-FLIPL cl. 32 and empty vector control cells with CD95L for 30 min 
compared with unstimulated samples. Immunoprecipitation was performed on Flag-agarose-beads. 
(A) 10% of samples were loaded onto an SDS-gel followed by Western blotting with analysis of the 
proteins CD95, FADD, c-FLIP and caspase-8 as control for efficient DISC formation. (B) The rest of the 
samples were run on an SDS-gel followed by gel fixation and coomassie-staining. Each lane was cut in 17 
gel slices as indicated and analysed by mass spectrometry. The immunoprecipitation shown is 
representative for two independent experiments. 
 
The core components of the DISC complex identified by mass spectrometry in the empty 
vector control cells were the CD95 receptor, caspase-8 and caspase-10. For the c-FLIPL 
overexpressing cells, the core components identified were the CD95 receptor, FADD, c-FLIP, 
caspase-8 and TRAF2 (Table 2). Surprisingly, FADD could not be detected in the empty 
vector control cells by mass spectrometry. However, FADD was identified in the control 
Western blot and DED-containing proteins such as caspase-8 and caspase-10 should not be 
able to bind to the DISC without an adaptor protein 246, 247. Caspase-10 was not identified in 
the DISC of c-FLIPL overexpressing cells. This is not unexpected since DED-containing 
proteins are competing for the binding sites at the DISC. It is therefore likely that the 
overexpression of c-FLIPL is outcompeting caspase-10-binding. 
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Furthermore, comparison of the DISCs revealed four potentially new DISC interacting 
proteins with c-FLIPL-dependent binding (Table 2). These proteins were the zinc finger 
protein A20 (Tumour necrosis factor alpha-induced protein 3), multiple myeloma tumour-
associated protein 2 (hMMTAG2), SAP domain-containing ribonucleoprotein (Hcc-1) and 
suppressor of SWI4 homologue (Ssf-1). 
 
Table 2. Core components of the DISC complexes in Jurkat empty vector and HA-c-FLIPL cl.32 cells 
according to MS data.  
Jurkat E6.1 empty vector Jurkat E6.1 HA-c-FLIPL cl.32 
CD95 CD95
caspase-8 FADD
caspase-10 c-FLIP
caspase-8
TRAF2
Potential candidates:
A20
Multiple myeloma tumour-associated protein 2
SAP domain-containing ribonucleoprotein
Suppressor of AWI4 homolog
 
 
The zinc finger protein A20 (hereafter called A20) is known to interact with the TNF-R1 
complex and thereby regulate NF-κB activation 248, 249. Reagents for this protein were 
available and therefore it was chosen for further validation. A20-association to the DISC was 
validated by immunoprecipitation of the DISC complex in both empty vector control cells and 
c-FLIPL overexpressing cells. The DISC complex assembled in both cell lines upon CD95L-
stimulation since the recruitment of CD95, FADD, caspase-8 and c-FLIP could be detected. 
TRAF2 only associated to the complex in c-FLIPL overexpressing cells consistent with the 
experiments described above. Indeed, A20 was recruited to the DISC upon CD95L-
stimulation, but a c-FLIPL-dependent DISC-recruitment of A20 could not be confirmed since 
A20-interaction was detected both in empty vector control cells and c-FLIPL overexpressing 
cells (Figure 30A). The DISC complex was identified in c-FLIPL-immunoprecipitates upon 
anti-CD95 stimulation and A20 was detected in this immunoprecipitation as well (Figure 
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30B). Ubiquitinylated RIP1 is described to activate NF-κB by interacting with the IκB kinase 
(IKK) complex 248, 250 and A20 regulates the NF-κB activation by de-ubiquitinylation of 
RIP1 249. Nevertheless, an association of the IKK complex subunits IKKα and IKKγ/NEMO 
with the DISC complex was not identified (Figure 30A, B). 
 
 
Figure 30. Immunoprecipitations of the DISC complex for analyses of novel interaction partners. Jurkat 
empty vector control cells and HA-c-FLIPL cl. 32 (A) or Flag-c-FLIPL cl. 16 (B) were either left untreated 
or stimulated with (A) CD95L (107cells per sample) or (B) 2 µg/ml anti-CD95 (2R2) crosslinked with 
10 ng/ml Protein A (3×107 cells per sample) for 30 min followed by immunoprecipitation on Flag-agarose 
beads. Interaction partners were identified by probing the Western blots with antibodies directed against 
CD95, FADD, caspase-8, c-FLIP, TRAF2, RIP1, A20, IKKα and IKKγ/NEMO.   
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4.3. Constitutive expression of murine c-FLIPR causes autoimmunity in 
aged mice 
4.3.1. Endogenous expression of murine c-FLIPR 
c-FLIPR has been described as the only short murine isoform of c-FLIP 142. However, the 
endogenous protein expression has not been shown so far. Human c-FLIPS is induced upon T 
cell activation 147, 175. To examine if murine c-FLIPR is induced in a similar way, lymph node 
cells were isolated from C57BL/6 WT mice followed by stimulation with either 
concanavalin A (Con A) or anti-CD3 and anti-CD28. Indeed, c-FLIPR expression was induced 
after 24 hours stimulation with Con A and remained expressed until 48 hours after stimulation 
started, whereas c-FLIPR was not detected in unstimulated lymph node cells (Figure 31A). 
Moreover, c-FLIPL was cleaved into the p43-fragment upon Con A stimulation, but caspase-8 
and FADD expression remained constant during Con A stimulation (Figure 31A).  
 
 
Figure 31. Endogenous c-FLIPR expression. (A) C57BL/6 WT lymph node cells were stimulated with 
2 µg/ml concanavalin A for the indicated times. The expression of c-FLIP, FADD and caspase-8 was 
analysed by Western blotting. Expression of β-actin was controlled to ensure equal loading. (B) Peripheral 
lymph node cells from C57BL/6 WT mice were stimulated for the indicated times in wells coated with 
2 µg/ml anti-CD3 and 2 µg/ml anti-CD28 in presence or absence of 20 µM Q-VD-OPh. Lysates were 
immunoblotted to analyse the expression of c-FLIP, caspase-8 and FADD. β-actin served as the loading 
control. Asterisks (*) mark unspecific bands. 
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Additionally, C57BL/6 WT lymph node cells were stimulated with plate-bound anti-CD3 and 
anti-CD28 for up to two days in presence or absence of the pan-caspase-inhibitor Q-VD-OPh 
in order to exclude that the 24 kDa band is a proteolytical fragment and not c-FLIPR. 
Moreover, the size of c-FLIPR was controlled by HEK293T cells transiently transfected with a 
plasmid encoding murine c-FLIPR. Consistent with Con A stimulation, c-FLIPR was induced 
after 24 hours stimulation and its expression was unaltered by the addition of Q-VD-OPh 
(Figure 31B). Low expression of c-FLIPR could still be detected after 48 hours, again not 
affected by the pan-caspase inhibitor. Although Q-VD-OPh did not completely inhibit 
c-FLIPL cleavage, expression of the p43-fragments was clearly impaired indicating that p43, 
but not the 24 kDa c-FLIPR band, originated from caspase-mediated cleavage (Figure 31B). 
Taken together, c-FLIPR is indeed being induced upon T cell activation similar to human 
c-FLIPS. 
4.3.2. The c-FLIPR transgenic mouse model - vavFLIPR 
The c-FLIPR transgenic mouse model vavFLIPR, generated by Prof. Dr. Ingo Schmitz 
(Helmholtz Centre for Infection Research, Brunswick, Germany and Institute for Molecular 
and Clinical Immunology, Otto-von-Guericke University, Magdeburg, Germany) was used to 
further examine the role of murine c-FLIPR in the immune system. 
In this mouse model, murine c-FLIPR is under control of the vav-promoter (Figure 32A) and 
therefore expressed in all hematopoietic compartments. The plasmid used for generating the 
transgenic construct was described by Ogilvy and colleagues 240 and Bcl-2 under control of 
the vav-promoter was successfully expressed throughout the hematopoietic compartment 251. 
Transgenic expression of c-FLIPR was controlled by PCR on tail biopsies, with β-actin as 
loading control (Figure 32B). Furthermore, c-FLIPR protein expression was controlled in the 
lymphoid organs thymus, spleen and peripheral lymph nodes (pLN). The expression of the 
DISC proteins caspase-8 and FADD remained unchanged (Figure 32C). The c-FLIPR 
expression in vavFLIPR mice was comparable to the endogenously expressed c-FLIPR in 
splenocytes induced by Con A (Figure 32D). c-FLIPL was cleaved into the cleavage product 
p43 and caspase-8 was processed into the p41/43 as well as p18 cleavage products upon 
Con A stimulation in splenocytes. This is consistent with previous studies where cleavage of 
caspases upon T cell receptor stimulation has been reported 210, 211. 
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Figure 32. The c-FLIPR transgenic mouse model - vavFLIPR. (A) The c-FLIPR gene with a C-terminal 
simian virus 40 (SV40) polyadenylation signal sequence was placed under control of the vav-promoter. 
This construct was used for generating c-FLIPR transgenic mice. (B) Expression of the transgenic c-FLIPR 
construct was controlled by PCR of tail biopsies. PCR of β-actin was used as loading control and PCR of 
water (H2O) as negative control. (C) Protein expression of c-FLIPR was controlled in thymic, splenic and 
peripheral lymph node (pLN) lysates from WT and vavFLIPR (Tg) mice by Western blotting. Antibodies 
directed against c-FLIP, caspase-8 and FADD were used with β-actin as loading control. (D) Splenocytes 
from WT and vavFLIPR animals were either left untreated (-) or stimulated with 2 µg/ml concanavalin A 
(Con A) for 64 hours (+). Subsequently cells were lysed and analysed by Western blotting as described 
above. 
4.3.3. vavFLIPR mice are protected against CD95-induced apoptosis and AICD  
c-FLIP proteins are well-known inhibitors of death-receptor mediated apoptosis 118, 140, 141, 149 
and cell lines overexpressing c-FLIPR are protected against apoptosis 140, 143. To analyse the 
functionality of the transgenic expression of murine c-FLIPR, thymocytes from WT and 
vavFLIPR mice were stimulated with CD95L or anti-CD95. Significantly more viable 
(AnnexinV- 7AAD-) cells were identified in stimulated samples from vavFLIPR mice 
compared with WT littermates (Figure 33B). Dexamethasone (Dex) is a synthetic 
glucocorticoid which induces apoptosis via binding to the glucocorticoid receptor 252, 253. 
Thus, Dex-induced apoptosis is independent of the death-receptor mediated pathway and both 
WT and vavFLIPR thymocytes had comparable frequencies of viable cells after Dex-
stimulation (Figure 33A, B). Furthermore, thymocytes from WT and vavFLIPR animals were 
stimulated with CD95L for up to eight hours to study the time-course of apoptosis. More early 
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apoptotic WT cells (AnnexinV+ 7AAD-) were identified after four hours stimulation 
compared with vavFLIPR cells (Figure 33C, D). After eight hours CD95L-stimulation, higher 
frequencies of both late apoptotic (AnnexinV+ 7AAD+) and early apoptotic WT cells were 
observed in comparison to vavFLIPR cells (Figure 33C, D). Thus, WT thymocytes were 
rapidly undergoing apoptosis, whereas vavFLIPR thymocytes were more resistant to CD95-
induced apoptosis.  
 
Figure 33. Analysis of CD95-mediated apoptosis in thymocytes from WT and vavFLIPR mice. (A, B) 
Thymocytes from WT and vavFLIPR animals were stimulated with 50 ng/ml CD95L, 1 µg/ml anti-CD95 
(Jo2) crosslinked with 10 ng/ml Protein A or 1 µM dexamethasone (Dex) for 16 h (WT n=4, vavFLIPR 
n=6). Apoptosis was analysed by AnnexinV and 7AAD staining. Representative dot plots are shown in (A). 
The percentages (mean ± s.e.m. of four independent experiments) of viable (AnnexinV- 7AAD-) cells for 
the different stimuli are shown in (B). Statistical analyses were performed with one-tailed non-parametric 
Mann-Whitney U tests; asterisks (*) indicate p < 0.05. (C, D) Thymocytes were stimulated with 50 ng/ml 
CD95L for 0, 2, 4 and 8 h (WT n=3, vavFLIPR n=3). Apoptosis was analysed by staining with AnnexinV 
and 7AAD measured by flow cytometry. Representative dot plots from one of two independent 
experiments are shown in (C). The percentages (mean ± s.e.m.) of viable (AnnexinV- 7AAD-) cells for the 
different stimuli are represented in (D). 
 
Next, the apoptosis sensitivity in peripheral T and B cells was examined. Sorted CD4+ and 
CD8+ T cells as well as CD19+ B cells were stimulated with CD95L and dexamethasone. 
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Significantly more viable (AnnexinV- 7AAD-) vavFLIPR CD4+ and CD8+ cells were 
identified compared with WT cells. The dexamethasone controls were comparable between 
WT and vavFLIPR cells (Figure 34A, B). Sorted CD19+ B cells were activated with LPS for 
two days to induce expression of the CD95 receptor before CD95L- and dexamethasone 
stimulation. The B cells were fairly insensitive towards both CD95L- and dexamethasone-
induced apoptosis. Nevertheless, the specific apoptosis of vavFLIPR B cells was significantly 
lower than the specific apoptosis of WT B cells (Figure 34C), whereas the specific apoptosis 
of dexamethasone-treated WT and vavFLIPR B cells was comparable (Figure 34D). 
 
 
Figure 34. Apoptosis sensitivity of peripheral T and B cells and analysis of activation-induced cell death 
(AICD). (A, B) Sorted CD4+ (A) and CD8+ T cells (B)  from peripheral lymphoid organs were stimulated 
with 50 ng/ml CD95L or 1 µM dexamethasone (Dex) for 16 h (WT n=4, vavFLIPR n=4). Apoptosis was 
analysed by AnnexinV and 7AAD staining. The percentages of viable (AnnexinV- 7AAD-) cells are 
represented as the mean ± s.e.m. from two independent experiments. (C, D) Sorted CD19+ B cells from WT 
(n=5) and vavFLIPR (n=4) mice were activated with 10 µg/ml LPS for 48 h. Apoptosis of activated B cells 
was assayed by stimulation with 100 ng/ml CD95L (C) or 1 µM Dex (D) for 16 h, followed by AnnexinV 
and 7AAD staining. The specific apoptosis of CD95L- and Dex-stimulated cells is shown as the mean ± 
s.e.m. from three independent experiments. (E) Peripheral lymph node cells from WT (n=4) and vavFLIPR 
(n=4) mice were activated with 10 µg/ml plate-bound anti-CD3, 2 µg/ml plate-bound anti-CD28 and 20 
ng/ml IL-2 for two days and further expanded in IL-2 containing medium for three days. On day five, T cell 
blasts were cultured with 10 µg/ml plate-bound anti-CD3 for 6 h to assess AICD. Apoptosis was analysed 
by AnnexinV and 7AAD staining. The specific apoptosis of anti-CD3 stimulated cells is displayed as the 
mean ± s.e.m. from two independent experiments. Statistical analyses were performed with one-tailed non-
parametric Mann Whitney U tests. 
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Reactivation of the T cell receptor leads to apoptosis by crosstalk with death receptors. The 
CD95 receptor has been shown to be involved in activation-induced cell death (AICD) 166-169. 
To assay AICD, peripheral lymph node cells from WT and vavFLIPR mice were isolated and 
T cells were activated for two days with plate-bound anti-CD3 and anti-CD28 in presence of 
IL-2. Activated T cells were further expanded for three days in medium containing IL-2. 
AICD was assessed on day five by restimulating T cells with plate-bound anti-CD3 to induce 
cell death. Cells from vavFLIPR mice showed significantly less specific apoptosis compared 
to WT cells (Figure 34E).  
The apoptosis assays confirm that vavFLIPR lymphocytes are protected against both CD95-
induced apoptosis and AICD.  
4.3.4. Normal cell populations in young vavFLIPR mice  
Lpr and gld mice with defective CD95 receptor and CD95 ligand respectively, show 
lymphoproliferative disease 155, 160, 254. c-FLIP proteins inhibit the same pathway, however 
total cellularity of thymus, spleen and pLN were normal to slightly reduced in 7-week old 
vavFLIPR mice compared with WT littermates (Figure 35). The CD4/CD8 profiles in the 
thymuses of vavFLIPR and WT mice were comparable (Figure 36 and table 3). 
 
 
Figure 35. Total cell number of lymphoid organs thymus, spleen and peripheral lymph nodes from 7-week 
old vavFLIPR mice (n=6) and wild type littermates (n=6). The data is shown as the mean ± s.e.m. from two 
independent experiments. 
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Figure 36. Cells from freshly isolated WT (n=6) and vavFLIPR (n=6) thymuses were stained for CD4 and 
CD8 followed by flow cytometry analysis. Representative dot plots are shown in (A). Frequencies of CD4+ 
single positive, CD4+CD8+ double positive (DP), CD4-CD8- double negative (DN) and CD8+ single 
positive cells from two independent experiments are shown in (B). Individual mice are shown as separate 
symbols. Horizontal lines represent the mean; error bars display s.e.m. 
 
The B cells and T cell subsets were analysed in spleen and peripheral lymph nodes from WT 
and vavFLIPR mice. Both frequencies and total cell numbers of CD19+ B cells, CD3+ T cells 
as well as the subsets CD4+ helper T cells, CD8+ cytotoxic T cells and CD4+CD25+ regulatory 
T (Treg) cells were comparable between 7-week-old littermate WT and vavFLIPR mice (Figure 
37, table 3).  
 
Table 3. Total cell numbers of CD3+, CD4+, DP, DN, CD8+, CD19+ and CD4+CD25+ in 7-week old WT 
and vavFLIPR mice (s.d. = standard deviation, n.d. not determined). 
Mouse strain Organ Total cell number ×106 (± s.d.)
(n=6) CD3+ CD4+ DP DN CD8+ CD19+ CD4+ CD25+
WT thymus n.d. 6.1 (2.0) 71.7 (30.8) 4.6 (3.2) 1.6 (0.6) n.d. n.d.
vavFLIPR thymus n.d. 4.7 (2.2) 55.5 (31.7) 3.2 (2.8) 1.3 (0.6) n.d. n.d.
WT spleen 13.2 (4.7) 7.1 (2.6) n.d. n.d. 4.7 (1.5) 15.3 (3.7) 0.6 (0.2)
vavFLIPR spleen 12.7 (4.5) 6.9 (2.8) n.d. n.d. 4.4 (1.5) 12.6 (4.6) 0.6 (0.3)
WT pLN 9.0 (2.1) 5.0 (1.2) n.d. n.d. 3.7 (0.9) 2.6 (1.2) 0.5 (0.2)
vavFLIPR pLN 6.8 (2.3) 4.0 (1.2) n.d. n.d. 2.5 (0.9) 2.0 (0.6) 0.4 (0.1)
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Figure 37. Freshly isolated splenocytes and peripheral lymph node cells (pLN) from WT (n=6) and 
vavFLIPR (n=6) mice were stained with antibodies directed against CD3, CD4, CD8, CD19 and CD25 
followed by FACS analysis. Representative dot plots are shown in (A). (B - F) Individual mice are shown 
as separate symbols. Horizontal lines represent the mean of frequencies from two independent experiments; 
error bars display s.e.m. (B) CD3+ T cells, (C) CD19+ B cells, (D) CD4+ T helper cells within the CD3+ 
compartment, (E) CD8+ cytotoxic T cells within the CD3+ subset and (F) CD4+CD25+ regulatory T cells 
within the CD3+ compartment.   
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Furthermore, the activation status of T cells was analysed in spleen and peripheral lymph 
nodes from 7 weeks old WT and vavFLIPR mice by CD44 and CD62L staining. No difference 
in CD44+ antigen-experienced T cells or CD62L+ naïve T cells could be observed (Figure 38). 
 
 
Figure 38. Flow cytometry analyses of activation status in 7-weeks old mice (n=6). (A) Representative dot 
plots of CD44 and CD62L cells within the CD3+ compartment from peripheral lymph nodes (left panel) 
and spleen (right panel). (B, C) Horizontal lines represent the mean of two independent experiments; error 
bars display s.e.m. Each symbol represents an individual mouse. The frequencies of CD44+, CD44+CD62L+ 
and CD62L+ in cells from peripheral lymph nodes (B) and splenocytes (C) are shown.  
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4.3.5. Experimental autoimmune encephalomyeliltis 
Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying the 
human demyelinating inflammatory disorder multiple sclerosis (MS) 255. The disease in the 
EAE model is caused by activated T cells with specific responses against myelin, which are 
migrating into the central nervous system (CNS) 256. Experiments where EAE was induced in 
Lewis rats indicated that autoreactive T cells in the CNS are eliminated by activation-induced 
cell death via the CD95-receptor pathway 257, 258. Therefore, the influence of constitutive 
murine c-FLIPR expression in T cells, macrophages and DCs in EAE disease progression was 
investigated. However, no differences between WT and vavFLIPR animals could be detected 
either in female (Figure 39A) or male mice (Figure 39B). 
 
Figure 39. MOG(35-55)-peptide-induced experimental autoimmune encephalomyelitis (EAE). Female (A) 
and male (B) WT and vavFLIPR (Tg/WT) mice were injected with the MOG-peptide and two subsequent 
injections of pertussis toxin, followed by 40 days of scoring according to table 1 (see 3.3.5.). Data is 
represented as the mean (± s.e.m.). 
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4.3.6. Altered cell populations in one year old vavFLIPR mice 
Insufficient cell death can lead to autoimmunity and alterations in cell populations. Lpr and 
gld mice develop lymphoproliferation disease 155, 160. Moreover, these mice accumulate CD4- 
CD8- double negative (DN) B220+ T cells 160, 161. WT and vavFLIPR littermates were aged to 
one year to examine the influence of constitutive expression of murine c-FLIPR. Peripheral 
lymph node cells of WT and vavFLIPR mice were analysed for DN B220+ cells with three 
months old MRL/lpr mice as control. The characteristic DN B220+ population was identified 
in MRL/lpr mice, but could not be detected in either WT or vavFLIPR animals (Figure 40), 
which is in agreement with c-FLIPL tg mice 215 and transgenic mice constitutively expressing 
human c-FLIPS 259. Furthermore, vavFLIPR animals did not show lymphoproliferation at one 
year of age. The cellularity of spleen and peripheral lymph nodes was normal in vavFLIPR 
mice (Figure 41). 
 
Figure 40. Analysis of DN B220+ cells in peripheral lymph nodes from 1 year old WT and vavFLIPR 
animals. Representative dot plots are shown. Three months old MRL/lpr (CD95 mutated) mice develop the 
characteristic DN B220+ cells (upper panel). This subset could not be found in either WT mice (mid panel) 
or vavFLIPR mice (lower panel). MRL/lpr n=2, WT n=6, vavFLIPR n=7. 
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Figure 41. Total cell number of spleen and peripheral lymph nodes (pLN) from 1 year old vavFLIPR (n=9) 
and WT mice (n=7). The mean ± s.e.m. is shown. 
 
Flow cytometry analyses of lymphocyte subpopulations in spleens and pLN from one-year-
old mice showed a slight reduction in both frequency and total cell number of vavFLIPR CD3+ 
cells compared with WT CD3+ cells. Nevertheless, CD4+ and CD8+ cell frequencies and total 
numbers were comparable between WT and vavFLIPR mice. Moreover, a minor increase in 
the frequency of vavFLIPR CD19+ cells compared with WT was observed. However, the total 
cell numbers of CD19+ cells were similar between WT and vavFLIPR mice. A slightly higher 
frequency of vavFLIPR CD4+CD25+ cells in comparison to WT cells was identified, but WT 
and vavFLIPR total cell numbers were similar (Figure 42). 
Next, the activation status in one year old WT and vavFLIPR mice was analysed. A slight 
increase in the frequencies of CD44+ antigen-experienced cells as well as lower frequencies of 
CD62L+ naïve cells could be identified in both peripheral lymph nodes and spleen of 
vavFLIPR mice compared with WT littermates. This was more pronounced in the spleen than 
peripheral lymph nodes, although the total cell numbers of CD44+ and CD62L+ cells were 
rather similar between WT and vavFLIPR mice (Figure 43). These data suggest that the higher 
frequency of CD4+CD25+ cells in vavFLIPR mice are rather activated T helper cells than Treg 
cells (Figure 42).  
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Figure 42. Analysis of B cells and T cell subsets by flow cytometry in 1 year old mice. (A) Representative 
dot plots of WT (n=7; upper panel) and vavFLIPR (n=9; lower panel) peripheral lymph node (pLN) cells. 
(B, D, F) Frequencies of CD3+ cells (B), CD19+ cells (D) and CD4+CD25+ cells (F) in freshly isolated 
peripheral lymph nodes and spleen. (C, E, G) Total cell numbers in peripheral lymph nodes and spleen of 
CD3+ cells (C), CD19+ cells (E) and CD4+CD25+ cells (G). Individual mice are represented as separate 
symbols. Horizontal lines show the mean of four independent experiments; error bars display the s.e.m. 
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Figure 43. Freshly isolated peripheral lymph node (pLN) cells and splenocytes from 1 year old WT and 
vavFLIPR mice were stained for the activation markers CD44 and CD62L followed by flow cytometry 
analysis. (A) Representative dot plots of peripheral lymph node cells (left panel) and splenocytes (right 
panel) from WT (n=7; upper panel) and vavFLIPR mice (n=9; lower panel). (B, D) Frequencies of CD44+, 
CD44+CD62L+ and CD62L+ cells from peripheral lymph nodes (B) and spleen (D). (C and E) Total cell 
numbers of CD44+, CD44+CD62L+ and CD62L+ cells from peripheral lymph nodes (C) and spleen (E). 
(B-E) Symbols represent individual mice. Horizontal lines represent the mean of four independent 
experiments; error bars display s.e.m. 
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Dendritic cells, macrophages and granulocytes have been reported to be regulated through 
death receptors and c-FLIP proteins 260, 261. Since vavFLIPR mice constitutively express 
murine c-FLIPR in all hematopoietic compartments, the frequencies of CD11c+ dendritic cells, 
CD49b+ natural killer (NK) cells, F4/80+ macrophages and Gr1+ granulocytes in one year old 
mice were analysed. The frequencies of CD11c+, CD49b+, F4/80+ and Gr1+ cells were 
comparable between WT and vavFLIPR mice (Table 4). 
 
Table 4. Frequencies of CD11c+, F4/80+, Gr1+ (WT n=4, vavFLIPR n=6) and CD49b+ (WT n=2, vavFLIPR 
n=4) cells within the CD3-CD19- compartment in spleen and bone marrow (BM) from 1 year old mice. 
(s.d. = standard deviation) 
Mouse strain Organ Frequency within CD3- CD19- subset (± s.d.) [%]
CD11c+ CD49b+ F4/80+ Gr1+
WT spleen 3.2 (2.7) 12.9 (2.8) 8.5 (7.4) 2.7 (1.7)
vavFLIPR spleen 3.8 (3.4) 12.0 (3.9) 8.5 (7.3) 5.0 (3.1)
WT BM 0.8 (0.2) 4.8 (1.6) 16.1 (7.5) 51.1 (8.5)
vavFLIPR BM 0.9 (0.5) 6.9 (2.5) 19.8 (14.8 ) 55.7 (21.2)  
 
4.3.7. Damage of kidneys and increased ANA-titers in one year old vavFLIPR mice 
Livers and kidneys of one year old WT and vavFLIPR animals were analysed by histology. 
H&E stained livers were scored according to damage observed (see 3.3.6.). No differences 
could be identified between WT and vavFLIPR mice. Furthermore, kidneys were stained with 
PAS followed by histological scoring (see 3.3.6.). vavFLIPR kidneys had higher histological 
scores compared with WT kidneys, which implies more damage of vavFLIPR kidneys than 
WT kidneys in one year old mice (Figure 44).  
Sera from one year old WT and vavFLIPR mice were analysed for anti-nuclear antibodies 
using an indirect immunofluorescence assay with HEp-2 cells as source of nuclear antigens. 
Significantly more autoantibodies could be identified in sera from vavFLIPR mice compared 
with WT mice. All WT animals, except one, had ANA-titers lower than serum dilution 1:320, 
whereas half of the vavFLIPR mice had ANA-titers at serum dilution 1:320 or higher (Figure 
45). 
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Figure 44. Histological scoring of H&E stained livers (A) and PAS stained kidneys (B) from 1 year old 
WT (liver n=10, kidney n=12) and vavFLIPR animals (liver n=13, kidney n=16). (A, B) Individual mice are 
displayed as separate symbols. Horizontal lines represent the mean; error bars show the s.e.m. (C, D) PAS 
staining of paraffin embedded kidneys; bar represents 25µm. (C) Normal glomerulum. (D) Glomerulum 
showing protein casts and thickening of the Bowman’s capsule.  
 
 
Figure 45. Anti-nuclear antibody (ANA) assay of sera from 1 year old WT (n=11) and vavFLIPR (n=14) 
mice. (A) Symbols represent individual mice. Horizontal lines represent the mean; error bars display s.e.m. 
(B) Examples of fluorescent homogenous pattern (positive) and negative fluorescent pattern. 
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5. Discussion 
5.1. The role of c-FLIP splice variants in urothelial carcinoma 
Apoptosis is crucial for maintaining tissue homeostasis and deregulation of apoptosis can lead 
to excessive cell growth and tumour formation 60. Indeed, resistance to cell death is one 
hallmark of cancer cells. The resistance can be mediated by high expression levels of anti-
apoptotic proteins 262. Commonly upregulated anti-apoptotic proteins of the intrinsic pathway 
are Bcl-2, Bcl-xL and inhibitor of apoptosis proteins (IAPs) 60, 262. The anti-apoptotic c-FLIP 
proteins inhibit apoptosis in the extrinsic pathway by preventing initiator caspase-activation at 
the signalling complex of death receptors 118, 149 and high expression levels of these proteins 
have been reported in various cancer types, i.e. melanoma 141, 191 and Hodgkin’s lymphoma 
189, 190
. Therefore, the lower expression of c-FLIPL in urothelial tumour tissue samples 
compared with normal tissue samples in this thesis was unexpected. The low c-FLIPL 
expression was confirmed in urothelial cell lines compared with normal urothelial cells. In 
contrast, c-FLIPS was not differentially expressed in either tissues or cell lines. Of note, a few 
tissue samples did not express c-FLIPS at all, most likely due to the presence of a functional 
SNP (rs10190751 A/G) in the CFLAR gene which determines whether c-FLIPR or c-FLIPS is 
produced 142. In the context of a former study 142, no significant changes in the distribution of 
this SNP between bladder cancer patients and controls were observed. 
A previous study analysed the expression of c-FLIP, CD95 and CD95L in urothelial 
carcinomas by immunohistochemistry 263. c-FLIP expression was observed in 81% of the 53 
urothelial tumour samples, with increasing CD95L and c-FLIP expression with advancing 
stage of tumour. Normal urothelium was negative for c-FLIP and CD95L, whereas concurrent 
expression of CD95 and CD95L could be seen in half of the patient samples with 81.5% of 
these samples also being positive for c-FLIP. This suggests that c-FLIP is protecting the cells 
against CD95-mediated apoptosis. Indeed, down-regulation of c-FLIP by shRNA in this thesis 
sensitised the urothelial carcinoma cell lines towards both CD95L and TRAIL-mediated 
apoptosis. This is consistent with a previous report where a function of c-FLIP in the TRAIL 
resistance of urothelial tumour cells was observed 264. 
The differential expression of c-FLIPS and c-FLIPL isoforms in urothelial carcinoma found in 
this thesis raises the question of the splice variants’ individual functions. The c-FLIP isoforms 
inhibit death-receptor mediated apoptosis by different mechanisms 149 and can even have 
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opposite outcomes on cell death 152, 153. Overexpression of c-FLIPL, c-FLIPS and c-FLIPR by 
transient transfections in the VMCub1 and SD model systems demonstrated the protective 
effect towards CD95-induced apoptosis of all three c-FLIP isoforms in urothelial carcinoma. 
There are no antibodies available which recognise specific c-FLIP isoforms, therefore it is not 
possible to distinguish the different c-FLIP isoforms in tissue samples by 
immunohistochemistry. To address the question of individual functions of the long and short 
c-FLIP splice variants in urothelial tumours, RNA interference was used to specifically 
knock-down c-FLIPS, c-FLIPL or both isoforms (c-FLIPL/S) by lentiviral infection of shRNAs 
targeting these isoforms. In contrast to lymphocytes, where c-FLIPS has a dominant role in the 
protection against CD95-mediated apoptosis during the expansion phase of an immune 
reaction 147, c-FLIPS only seems to have a supporting function in urothelial carcinoma. 
Instead, c-FLIPL was observed to play a more pronounced role in the apoptosis resistance of 
urothelial tumour cells. Single knock-down of c-FLIPL in SD cells was sufficient to sensitise 
the cells towards apoptosis induced by the death ligands CD95L and TRAIL. Importantly, 
complete knock-down of c-FLIP resulted in similar apoptosis levels as the co-treatment with 
CHX. This suggests that c-FLIP is the main short-lived anti-apoptotic protein in these cells. 
The VMCub1 cells responded somewhat different to death receptor stimulation; single knock-
downs of c-FLIPL or c-FLIPS only slightly sensitised cells towards apoptosis. Minor cleavage 
of caspase-8 and -3 upon both CD95L- and TRAIL-stimulation was observed in VMCub1 
cells with single knock-downs. This suggests that the c-FLIP isoforms are not 
complementary. Indeed, different functions of the long and short c-FLIP isoforms have been 
reported. c-FLIPS is particularly important in the activation phase of immune responses where 
it is upregulated to protect effector T cells from apoptosis, whereas c-FLIPL levels remain 
stable 174, 175. Moreover, c-FLIPL can have both pro- and anti-apoptotic functions, whereas 
only anti-apoptotic functions have been reported for c-FLIPS 149, 151, 152.  A pronounced effect 
on the apoptosis susceptibility in VMCub1 cells was only identified when both c-FLIP 
isoforms were knocked down. This indicates that both c-FLIP isoforms contribute to the 
apoptosis resistance in VMCub1 cells. Thus, cells can be sensitised by reducing the total 
c-FLIP levels below the protection threshold. The complete knock-down of c-FLIP in VMCub 
cells resulted in partial sensitisation compared with co-treatment with CHX. Consequently, 
additional factors apart from c-FLIP contribute to the apoptosis resistance in the VMCub1 cell 
line. Possibly, the VMCub1 cells are of type II in respect to the death receptor-mediated 
apoptosis. In contrast to type I cells, type II cells have less efficient DISC formation and 
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caspase-8 activation, therefore the death signals are amplified over the mitochondrial pathway 
in these cells 114, 115. Of note, elevated expression of Bcl-2 and Bcl-xL was found in the 
previous characterisation of VMCub1 cells in the working group, which may contribute to the 
resistance against death receptor-mediated apoptosis 237.  
The downregulation of c-FLIPL observed in patient samples was surprising. High expression 
of an anti-apoptotic molecule would be thought to be beneficial for tumour survival and 
growth and this finding seems counterintuitive at first. However, CD95 signalling has been 
reported to have other functions in tumour cells. Tumour growth as well as the motility and 
invasiveness of tumour cells, especially in apoptosis-resistant tumours, can be promoted by 
CD95 signalling 199, 200. The non-apoptotic functions of CD95 signalling require activation of 
the NF-κB and MAP kinase pathways. However, high c-FLIP expression was shown to 
reduce the activation of these pathways 200, 265-267. This suggests that it is necessary for cancer 
cells to fine-tune the c-FLIP expression to optimise the effects of apoptosis inhibition and 
NF-κB/MAP kinase activation. Moreover, c-FLIPL has dual functions; the protein has an anti-
apoptotic function at high expression levels, whereas it becomes pro-apoptotic at low 
expression levels 153. Caspase-8 is more efficiently activated in heterodimers of 
c-FLIPL/caspase-8 than homodimers of caspase-8 itself at the DISC 268, 269. The enzymatically 
inactive caspase-like domain of c-FLIPL induces the enzymatic activity of the caspase-8 
protease domain, resulting in autoproteolytical cleavage and activation of the caspase-8 
molecule 151, 152, 268, 269. Furthermore, c-FLIPL acquires pro-apoptotic function in presence of 
high c-FLIPS expression 153. Since c-FLIPS is also expressed in urothelial carcinoma cells, 
downregulation of c-FLIPL may be beneficial to prevent its proapoptotic activity. 
At last, c-FLIPL and c-FLIPS are interplaying with the activation of the ripoptosome, a 
recently discovered multiprotein complex 270, 271. Optimal c-FLIPL and c-FLIPS expression 
levels and ratio may be required to prevent activation of this cell death-inducing platform. The 
ripoptosome can initiate either apoptosis or necroptosis, depending on its molecular 
composition 270, 271. RIP1 and RIP3 activation leads to necroptosis, whereas caspase-8 can 
cleave these kinases and thus, favours apoptosis. Interestingly, the c-FLIPS inhibition of 
caspase-8 cause increased levels of RIP1 in the ripoptosome and thereby activation of RIP3. 
This may promote necroptosis. In contrast, c-FLIPL and caspase-8 prevent ripoptosome 
formation, and thus inhibit necroptosis. Since necroptosis cause inflammation and thereby 
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attracts immune cells which can eliminate the tumour cells, it might be important for the 
development of urothelial carcinoma to inhibit ripoptosome assembly by c-FLIPL.  
Taken together, c-FLIP proteins, especially c-FLIPL, are important resistance factors in 
urothelial carcinomas. Therefore, targeting c-FLIP in CD95L- and TRAIL-based therapies 
could be a promising approach to treat urothelial tumours.  
5.2. Identification of novel CD95 DISC-interacting proteins  
Even though the death-inducing signalling complex (DISC) has been studied for many years, 
the complexity of the platform and involved proteins in transducing both death and survival 
signals is not yet fully understood. Recently, the model of the DISC complex and its 
stoichiometry was reconsidered. It was assumed that there is a one to one ratio between the 
adaptor protein FADD and DED-containing proteins until two independent studies on the 
DISC complexes assembled at CD95 and TRAIL receptors were published 228, 229. These 
reports gave evidence for chain formation of DED-proteins at CD95 and TRAIL receptor 
complexes. There are still open questions concerning the signalling pathways originating from 
the DISC. In this thesis the core components of the CD95 DISC under normal and c-FLIPL 
high circumstances were investigated by mass spectrometry. Moreover, the mass 
spectrometry data was used to identify novel DISC-interacting proteins.  
The cell system chosen for mass spectrometry analysis was the Jurkat E6.1 cell line. This cell 
line was considered advantageous over the use of primary cells for different reasons. There 
are no constraints in protein amount compared with primary cells where it can be difficult to 
obtain the protein amount needed for mass spectrometry analyses. Moreover, it is a well-
characterised model system and different knock-out cell lines are available 243-245, which could 
be useful for the characterisation of a potential novel DISC-binding protein. Jurkat clones 
stably overexpressing c-FLIPL as well as empty vector control cells were generated. c-FLIPL 
is known to inhibit apoptosis 118, 141 and it was confirmed in this thesis that Jurkat clones 
overexpressing c-FLIPL were protected against CD95-mediated apoptosis. Death receptor 
expression of empty vector control cells and c-FLIPL overexpressing cells was comparable 
and thus, did not influence the level of apoptosis. Furthermore, c-FLIP has been described as 
an activator of NF-κB 204, 206-208. Consistently, prolonged expression of phosphorylated IκBα 
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as well as increased expression of total IκBα was observed in c-FLIPL overexpressing clones. 
Thus, the Jurkat clones had functional expression of c-FLIPL. 
The CD95 DISC was immunoprecipitated with somewhat different composition in empty 
vector control cells and cells overexpressing c-FLIPL. The high amount of c-FLIP and low 
amount of caspase-8 recruited to the DISC in c-FLIPL overexpressing clones is explained by 
the competition of DED-containing proteins for the same binding sites 118. In addition, c-FLIP 
proteins have a higher affinity to these binding sites than caspase-8 118. Minute amounts of 
RIP1 were immunoprecipitated with slightly more protein, possibly ubiquitinylated, being 
detected in the DISC of c-FLIPL overexpressing cells. The DISC complex was also identified 
in c-FLIPL-immunoprecipitates upon anti-CD95 stimulation. Interestingly, RIP1 cleavage was 
observed, which could not be detected in the CD95L-immunoprecipitation. This could be 
caused by a different composition or localisation of the complex. Moreover, TRAF2 was 
recruited to the DISC in a c-FLIPL-dependent manner, which is consistent with the study of 
Kataoka and colleagues 206. The low amount of RIP1 identified at the DISC might be 
explained by a study which identified more efficient recruitment of RIP1 to the CD95 DISC 
upon stimulation with membrane-bound CD95L than stimulation with soluble CD95L or 
agonistic antibodies 272, the latter used in this thesis. The functions of RIP1 and TRAF2 in 
NF-κB activation have been studied for the TNF-R1 complex. Binding of TNFα to TNF-R1 
leads to activation of the receptor and recruitment of the adaptor protein TRADD as well as 
RIP1 and TRAF2 273. TRAF2 was reported to polyubiquitinylate RIP1 at the TNF receptor 
complex 250, which leads to activation of the NF-κB signalling cascade 274, 275. Interestingly, a 
recent study by Gonzalvez and colleagues gave evidence for ubiquitinylation of caspase-8 by 
TRAF2 at the TRAIL-DISC 276. The Lys48-linked ubiquitinylation of caspase-8 cleavage 
products p43 and p18 direct these fragments to proteosomal degradation, thereby ceasing the 
caspase-8 activity 276. It is possible that the c-FLIPL-dependent association of TRAF2 to the 
CD95 DISC could be a additional mechanism by which c-FLIP proteins modulate caspase-8 
activity. Still, the roles of RIP1 and TRAF2 need to be further characterised in the CD95 
signalling pathway. It is not clear how c-FLIPL facilitates the binding of TRAF2 to the CD95 
DISC. If there is a direct binding of c-FLIPL and TRAF2, the binding regions should be 
identified. Alternatively, c-FLIPL could have a stabilising effect on TRAF2- and/or RIP1-
binding.  
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The core components of the CD95 DISC were confirmed to be the CD95 receptor itself as 
well as caspase-8 and caspase-10 for the empty vector control cells. Peculiarly, FADD was 
not detected in the empty vector DISC by mass spectrometry analysis even though it was 
clearly identified by Western blotting. Further, caspase-8 and -10 cannot be recruited to the 
DISC without FADD 246, 247. Recent studies reported up to nine times more DED-containing 
proteins than FADD at the CD95 and TRAIL DISCs due to chain-formation of the DED-
containing proteins 228, 229. Consistent with these reports, it is likely that under the conditions 
used, the mass spectrometry was not sensitive enough to detect the low abundance of FADD 
at the DISC. Similarly, c-FLIP proteins have low expression levels in the empty vector 
control cells. This could explain why c-FLIP was not detected by mass spectrometry in the 
DISC of these cells. The CD95 DISC core components for the c-FLIPL overexpressing cells 
were the CD95 receptor, FADD, caspase-8, c-FLIP and TRAF2. Due to the low expression 
level of caspase-10, c-FLIPL outcompete caspase-10 at the DISC in c-FLIPL overexpressing 
cells. The slightly different composition of this DISC compared with the DISC of control cells 
possibly allows the detection of FADD. Mass spectrometry analyses could not identify RIP1 
as a DISC-interacting protein in either empty vector control cells or c-FLIPL overexpressing 
cells. This may be due to the low amount of RIP1 binding to the CD95 DISC. 
Interestingly, the mass spectrometry analyses revealed the proteins A20, hMMTAG2, Hcc-1 
and Ssf-1 as potential novel CD95 DISC-associating proteins with c-FLIPL-dependent 
recruitment. The protein hMMTAG2 is linked to tumour transforming activities, Hcc-1 is a 
DNA-binding protein and Ssf-1 is a splicing factor 277-279. Not much is known about these 
three proteins, but due to the nuclear localisation of Hcc-1 and involvement of Ssf-1 in 
mRNA splicing it seemed unlikely that these proteins would comprise functions in the DISC 
complex 278, 279. There are no functional studies on hMMTAG2, the zinc finger protein A20 
on the other hand has been implicated in NF-κB signalling at the TNF-R1 complex 248, 249. 
Furthermore, reagents for A20 were available and therefore validation and further 
characterisation first concentrated on this protein. Western blot analyses could confirm the 
binding of A20 to the DISC. However, a c-FLIPL-dependent recruitment to the DISC could 
not be verified. A20 has been studied in the TNF-R1 receptor complex 248 where it can cease 
NF-κB activation by removing Lys63-linked polyubiquitin chains of RIP1. Thereafter, A20 
can re-ubiquitinylate RIP1 with Lys48-linked polyubiquitin chains, which facilitates 
proteosomal degradation of the protein 249. Hence, A20 is an ubiquitin editing enzyme and a 
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regulator of NF-κB activation. However, the association of A20 with the CD95 DISC has so 
far not been reported. A20 is known to interact with TRAF2 280 and could possibly thereby 
associate with the CD95 DISC. It remains to be clarified if the activation of NF-κB through 
c-FLIPL is regulated by A20. Further investigations are necessary to elucidate how A20 binds 
to the CD95 DISC and if the binding is c-FLIP-mediated or not. Moreover, the function of 
A20 at the CD95 DISC is not clear and remains to be examined. 
5.3. Constitutive expression of murine c-FLIPR causes autoimmunity in 
aged mice  
The murine Cflar gene structure only allows expression of c-FLIPR as short c-FLIP splice 
variant 143. Nevertheless, up to this date c-FLIPR expression on the protein level has not been 
identified and it is not clear if this isoform has any functional relevance. Endogenous 
expression of c-FLIPR in lymph node cells was detected upon activation with Con A or anti-
CD3/anti-CD28 in this thesis. A similar upregulation of human c-FLIPS was reported in short-
term activated human T cells and was shown to be responsible for the protection against 
CD95-mediated apoptosis 147, 175.  
To further investigate the function of c-FLIPR in the immune system, transgenic mice were 
used with murine c-FLIPR under control of the vav-promoter to ensure expression in all 
hematopoietic compartments. Thymocytes as well as peripheral B and T cells from vavFLIPR 
mice were protected against CD95-induced apoptosis when induced by CD95L or agonistic 
antibodies, as expected. The death-receptor independent cell death induced by dexamethasone 
was not impaired in these lymphocytes. This implies that the transgenic c-FLIPR expression is 
functional. Furthermore, activated T cells from vavFLIPR mice were less sensitive towards 
cell death by restimulation of the T cell receptor. This finding is in contrast to the study of 
Lens and colleagues 215, where overexpression of c-FLIPL did not protect murine T cells 
against AICD. However, particularly c-FLIPS is induced upon co-stimulatory signals, such as 
CD28, and was described to protect human T cells from AICD 281. c-FLIPR might have a 
similar role in the mouse. 
The T and B cell compartments were normal in young vavFLIPR mice. This is consistent with 
previous reports of T cell specific expression of human c-FLIPS in mice 209, 259. Notably, a 
slight reduction in the thymus cellularity of vavFLIPR mice was observed. Reduced 
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thymocyte numbers were also reported for v-FLIP transgenic mice 282, 283. Tai and colleagues 
described the same phenomenon for T cell specific c-FLIPL transgenic mice 284. However, 
reduced thymus cellularity was not observed in further studies on c-FLIPS 209, 259 and 
c-FLIPL 215 transgenic mice. It is not clear why there are differences between the mouse 
models. Possible explanations are differences in the transgenic expression levels or the 
integration sites of the transgenic constructs. 
The regulation of apoptosis is critical during embryonic development. c-FLIP knock-out mice 
die at day 10.5 of embryogenesis due to defects in vascularisation of the yolk sac and cardiac 
failure 201. c-FLIP is also crucial for T cell development 216, 217. CD4+ and CD8+ single 
positive T cells did not fully mature in the thymus of mice with T cell specific conditional 
knock-out of c-FLIP 216. Moreover, transgenic mice expressing c-FLIPL in a T cell specific 
manner show disturbed T cell development and altered thymic selection 284, 285. In contrast to 
c-FLIPL transgenic mice, alterations in T cell cellularity, frequencies of the main T cell 
subsets or activation status could not be identified in young vavFLIPR mice. Thus, it is not 
likely that c-FLIPR has a functional role in T cell development. 
When EAE was induced in mice with mutated CD95 155, prolonged and enhanced 
inflammation was observed in the CNS 286. Hence, CD95/CD95L interactions are of 
importance to delete disease-initiating, autoreactive T cells in the CNS in the course of EAE. 
Both long and short c-FLIP isoforms have been reported to be upregulated in activated T cells 
from the cerebral spinal fluid in patients with active multiple sclerosis 287, 288. Interestingly, 
transgenic mice overexpressing human c-FLIPL were resistant to EAE 289. However, the 
progress of EAE in vavFLIPR and WT littermates was comparable. The autoimmune 
inflammation in EAE is mainly caused by Th1 and Th17 effector cells 256. Since transgenic 
c-FLIPL expression enhances Th2 effector responses 289-291, it is likely that c-FLIPL-
expressing T cells can suppress the development of Th1-mediated autoimmune disease. 
Transgenic expression of c-FLIPR or c-FLIPS has so far not been reported to alter the cytokine 
production of T cells in this way, which may be one reason why the transgenic expression of 
c-FLIPR did not influence the progression of EAE. Furthermore, the opposing observations 
could be caused by the different transgenic constructs used; human c-FLIPL under control of 
the CD2 promoter versus vav-promoter-driven murine c-FLIPR transgenic expression, which 
most probably also influence the transgenic expression levels. 
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Lpr and gld mice with mutations in the CD95 receptor and ligand respectively, rapidly 
develop lymphoproliferative disease and autoimmunity 155, 160. Furthermore, lpr/gld mice have 
altered lymphocyte populations and accumulate DN B220+ cells 161, 292. c-FLIP inhibits the 
same apoptosis pathway by preventing caspase-8 cleavage at the DISC 118, 149. Indeed, T cell 
specific c-FLIPL transgenic mice were reported to develop autoimmunity when bred on 
Balb/c, but not C57BL/6, background 285. It was therefore of interest to examine if 
constitutive expression of murine c-FLIPR in all hematopoietic compartments would lead to a 
similar phenotype. Up to one year old vavFLIPR mice had normal cellularity of spleen and 
lymph nodes. Moreover, no accumulation of DN B220+ cells could be identified. 
Consistently, transgenic mice with T cell specific expression of murine c-FLIPL or human 
c-FLIPS did not develop a lpr/gld phenotype 209, 215, 259. However, whether 
lymphoproliferative disease develops or not seems to be influenced by the expression level of 
FLIP as well as in which tissues the transgene is expressed. Notably, transgenic mice 
expressing the viral FLIP MC159 from the human Molluscum contagiosum virus under 
control of a CD2 enhancer cassette did not develop lymphoproliferation 282. On the contrary, 
the lpr/gld phenotype was observed when MC159 was placed under control of the ubiquitous 
MHC class I H2Kb promoter 293. However, heterozygous MC159-expression was insufficient 
since lymphoproliferation and autoimmunity only was observed in mice with homozygous 
expression of MC159 293. These studies imply that death-receptor-mediated apoptosis in non-
T cells plays a central role in preventing autoimmunity. This was further emphasised in a 
study by Stranges and colleagues where lack of CD95 expression in dendritic cells resulted in 
systemic autoimmunity 187. Even though vavFLIPR mice express c-FLIPR in all hematopoietic 
compartments, the animals are bred heterozygously, which might give a too low expression 
level of c-FLIPR to recapitulate the lpr/gld phenotype. 
B and T cell numbers and distribution were normal in young vavFLIPR mice and no 
differences in dendritic cells, macrophages, granulocytes or NK cells could be identified even 
in mice at one year of age. However, one year old vavFLIPR mice had slightly lower 
frequencies of T cells and somewhat higher frequencies of B cells compared with WT 
littermates. Moreover, alterations in the ratio antigen-experienced/naïve T cells were 
observed. Human c-FLIPS is upregulated in the activation and expansion phase of an immune 
reaction, but is thereafter down-regulated to enable elimination of effector T cells 281. Some 
effector cells survive and differentiate into memory T cells 164. Evidence is provided in this 
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thesis that murine c-FLIPR is the functional orthologue of human c-FLIPS. Indeed, increased 
frequencies of activated T helper cells and antigen-experienced T cells as well as lower 
frequencies of naïve T cells were identified in vavFLIPR mice in comparison to WT mice. 
This is consistent with a previous report where an increased memory T cell pool was 
identified in c-FLIPS transgenic mice compared with WT animals after immunisation with the 
superantigen staphylococcal enterotoxin B 259. Interestingly, histological analyses of kidneys 
from one year old mice revealed more tissue damage in kidneys from vavFLIPR mice in 
comparison to WT littermates. Moreover, elevated levels of antinuclear auto-antibodies were 
identified in sera from vavFLIPR animals at one year of age. These findings indicate that 
vavFLIPR mice develop a mild lupus-like phenotype. It is unclear which cell types are 
responsible for the autoimmunity in vavFLIPR mice. Persisting CD4+ helper T cells could 
possibly prime B cells to produce auto-antibodies. Qiao and colleagues described lupus-like 
disease in c-FLIPL transgenic mice on the Balb/c background. The development of 
autoimmunity in this study required CD4+ T cells and these cells were proposed to result from 
impaired thymic selection 285. Nevertheless, the thymus profiles were normal in young 
vavFLIPR mice and no alteration of CD4+ cell frequencies and total cell numbers could be 
identified in one year old vavFLIPR animals. The slightly increased frequency of B cells in 
vavFLIPR mice at one year of age could give another clue to the auto-antibody production. It 
remains to be investigated if B cells in aged vavFLIPR animals are hyperactivated. 
Taken together, this thesis gives evidence for that c-FLIPR is a functional orthologue of 
human c-FLIPS and plays a role in the activation phase of the immune system. Young 
vavFLIPR mice have unaltered lymphocyte populations, though the activated and antigen-
experienced T cell populations increase as the mice become older. Moreover, these animals 
develop mild lupus-like symptoms with age. 
5.4. Concluding remarks 
The strict regulation of apoptosis is crucial for multicellular organisms. Insufficient apoptosis 
may result in diseases such as cancer or autoimmunity. The role of c-FLIP isoforms in 
urothelial carcinoma was investigated in this thesis. Interestingly, diminished c-FLIPL 
expression was observed in both urothelial carcinoma tissues and established carcinoma cell 
lines compared with normal tissue and cells. In contrast, c-FLIPS expression was comparable 
between tumour and normal tissues/cell lines. In spite of these observations, c-FLIP proteins, 
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especially c-FLIPL, were identified as important resistance factors in CD95- and TRAIL-
mediated apoptosis in urothelial carcinoma. It is presumably necessary for tumours to fine-
tune the c-FLIP expression to achieve an optimal balance between the anti-apoptotic and 
proliferative signalling of c-FLIP proteins. 
Notably, mice with constitutive expression of c-FLIPR develop autoimmunity. One year old 
vav-FLIPR mice had increased levels of antigen-experienced T cells and reduced levels of 
naïve T cells compared with wild-type mice. Moreover, a higher degree of kidney damage 
and increased titers of autoantibodies were observed in one-year-old vavFLIPR mice in 
comparison to wild-type littermates. These mild lupus-like symptoms develop over time due 
to reduced apoptosis sensitivity. 
Taken together, these findings underline the importance of careful control of apoptosis. 
Moreover, c-FLIP could be a relevant target in diseases where apoptosis is deregulated. 
The DISC-interacting proteins c-FLIP, caspase-8 and FADD are reported to activate NF-κB 
signalling 204-207. However, it is not fully understood how these proteins switch between 
apoptosis and proliferative signalling. The novel CD95 DISC interaction partner A20 was 
identified in this thesis. It remains to be investigated what role A20 plays in the life and death 
decisions of CD95. 
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6. Abbreviations 
7AAD  7-amino-actinomycin D 
A1  Bcl-2-related protein A1 
ACN  acetonitrile 
AICD   activation-induced cell death 
AIF   apoptosis-inducing factor 
ALPS   autoimmune lymphoproliferative syndrome 
ANA  antinuclear antibody 
Apaf-1  apoptotic protease-activating factor-1 
APC   antigen presenting cell 
APP  β-amyloid precursor protein 
Atg3   autophagy-related protein 3 
Bad   Bcl-2 antagonist of cell death 
Bak   Bcl-2 antagonist killer 1 
Bax   Bcl-2-associated x protein 
BCA  bicinchoninic acid 
Bcl-2  B cell lymphoma-2 
Bcl-w   Bcl-2-like protein 2  
Bcl-xL   Bcl-lymphoma-extra large 
BH domains   Bcl-2 homology domains  
Bid   Bcl-2 interacting domain death agonist 
BIC  ammonium hydrogencarbonate 
Bik   Bcl-2-interacting killer 
Bim   Bcl-2-interacting mediator of cell death 
BM  bone marrow 
Bmf   Bcl-2 modifying factor 
Bok   Bcl-2-related ovarian killer 
CAD   caspase activated DNAse 
CARD  caspase recruitment domain 
CD  cluster of differentiation 
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CD95L  CD95 ligand 
C. Elegans   Caenorhabditis elegans 
c-FLIP  cellular FLICE-inhibitory protein 
c-FLIPL   cellular FLICE-inhibitory protein long isoform 
c-FLIPR   cellular FLICE-inhibitory protein Raji 
c-FLIPS   cellular FLICE-inhibitory protein short isoform 
Con A  concanavalin A 
CHX  cycloheximide 
CNS  central nervous system 
DcR  decoy receptor 
DD  death domain 
DED  death effector domain 
Dex  dexamethasone 
Diablo   direct binding IAP protein with low pI 
DISC  death-inducing signalling complex 
DMEM  Dulbecco’s modified Eagle’s medium 
DN   double negative (CD4-CD8-) 
DNA  deoxyribonucleic acid  
DP  double positive (CD4+CD8+) 
DP5  death protein 5 
DR  death receptor 
EAE   experimental induced encephalomyelitis 
E. coli  Escherichia coli 
EndoG   endonuclease G 
ER   endoplasmic reticulum 
EtBr  ethidium bromide 
FADD  Fas-associated death domain 
FCS  fetal calf serum 
FLIP  FLICE-inhibitory protein 
FLICE  FADD-like IL-1β-converting enzyme 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
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GFP  green fluorescent protein 
gld  generalized lymphoproliferative disease 
H&E  hematoxylin and eosin 
HA  hemagglutinin 
HEK293T  human embryonic kidney 293T 
HMGB1  high mobility group protein B1 
Hrk   Harakiri 
hu  human 
ICAD   inhibitor of caspase activated DNAse 
ICAM3   intercellular adhesion molecule-3 
IFN-γ   interferon-γ 
Ig  immunoglobulin 
IκB   inhibitor of NF-κB protein 
IKK complex  IκB kinase complex  
IL  interleukin 
IMDM  Iscove’s modified Dulbecco’s medium 
iono  Ionomycin 
IP  immunoprecipitation 
IRES  internal ribosomal entry site 
LC  liquid chromatography 
LOX1   oxidized low-density lipoprotein-1 
LV  lentivirus 
lpr  lymphoproliferation 
LPS  lipopolysaccharide 
LT  lymphotoxin 
MAP   mitogen-activated protein 
Mcl-1  myeloid cell leukemia 1 
MFG-E8   milk fat globule–EGF factor-8 protein  
MHC   major histocompatibility complex 
mk  monkey 
mLN  mesenteric lymph nodes 
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MOMP   mitochondrial outer membrane permeabilisation 
mRNA  messenger RNA 
ms  mouse 
MS  mass spectrometry 
Mule   Mcl-1 ubiquitin ligase E3 
n.d.  not determined 
NFAT  calcineurin-nuclear factor of activated T cells 
NF-κB  nuclear factor κB 
NK cells   natural killer cells 
NUC  normal urothelial cells 
OPG  osteoprotegerin 
OPGL  osteoprotegerin ligand 
PAS  periodic acid schiff 
PCR  polymerase chain reaction 
PE   phosphatidylethanolamine 
pLN  peripheral lymph nodes 
PMA  phorbol-12-myristate-13-acetate 
Puma   p53-upregulated modulator of apoptosis 
QVD-Oph  quinoline-Val-Asp-difluorophenoxymethylketone 
RIP  receptor-interacting protein 
RNA   ribonucleic acid 
ROCK I   Rho-associated coiled-coil-containing protein kinase I 
ROS  reactive oxygen species 
rt  rat 
S. aureus  Staphylococcus aureus 
s.d.  standard deviation 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
s.e.m.  standard error of the mean 
shRNA  short hairpin RNA 
Smac   second mitochondria-derived activator of caspase 
SNP  single nucleotide polymorphism 
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SP   single positive 
SPF  specific pathogen free 
SV40  simian virus 40 
tBid   truncated Bid 
TBP  TATA-binding protein 
TCR   T cell receptor 
TFA  trifluoreacetic acid 
TGF-β  transforming growth factor β  
TIM4   T cell immunoglobin domain and mucin domain protein 4 
Th1/2  T helper type 1/2 
TM   transmembrane domain 
TMRE  tetramethylrhodamine ethyl ester 
TNF  tumour necrosis factor 
TNF-R  tumour necrosis factor receptor 
Treg cells  regulatory T cells   
TRADD  TNF receptor-associated death domain protein 
TRAF2  TNF receptor-associated factor 2 
TRAIL  TNF-related apoptosis-inducing ligand 
TRAIL-R  TNF-related apoptosis-inducing ligand receptor 
TSP   thrombospondin 
v-FLIP  viral FLICE-inhibitory protein 
WAH-1  worm apoptosis-inducing factor homologue 
WT  wild-type 
XIAP   x-linked inhibitor of apoptosis protein 
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